UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30~~March 31, ~~2021~~2022

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File Number: 1-36282

LA JOLLA PHARMACEUTICAL COMPANY

(Exact name of registrant as specified in its charter)

Delaware		33-0361285
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

201 Jones Road, Suite 400, Waltham, MA		02451
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 715-3600

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

LJPC

The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~October~~April 22, ~~2021~~2022 there were 2725,~~524~~556,~~028~~239 shares of common stock outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION Item 1. Financial Statements 1 Condensed Consolidated Balance Sheets as of September 30, 2021 (Unaudited) and December 31, 2020 1 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2021 and 2020 (Unaudited) 2 Condensed Consolidated Statements of Shareholders’ Deficit for the Three and Nine Months Ended September 30, 2021 and 2020 (Unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2021 and 2020 (Unaudited) 5 Notes to Condensed Consolidated Financial Statements (Unaudited) 6 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3. Quantitative and Qualitative Disclosures about Market Risk 27 Item 4. Controls and Procedures 27 PART II. OTHER INFORMATION 28 Item 1. Legal Proceedings 28 Item 1A. Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 28 SIGNATURES 29

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements	1

Condensed Consolidated Balance Sheets as of March 31, 2022 (Unaudited) and December 31, 2021	1

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2022 and 2021 (Unaudited)	2

Condensed Consolidated Statements of Stockholders’ Deficit for the Three Months Ended March 31, 2022 and 2021 (Unaudited)	3

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2022 and 2021 (Unaudited)	4

Notes to Condensed Consolidated Financial Statements (Unaudited)	5

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3. Quantitative and Qualitative Disclosures about Market Risk	23

Item 4. Controls and Procedures	23

PART II. OTHER INFORMATION	24

Item 1. Legal Proceedings	24

Item 1A. Risk Factors	24

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3. Defaults upon Senior Securities	24

Item 4. Mine Safety Disclosures	25

Item 5. Other Information	25

Item 6. Exhibits	26

SIGNATURES	27

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Balance Sheets

(in thousands, except par value and share amounts)

	September 30,			December 31,
	March 31,			December 31,
	2021			2020
	2022			2021
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	4644,~~765~~169		$	2146,~~221~~668
Accounts receivable, net		8,793			5,834
Short-term investments		390			-
Inventory, net		6,094			6,013
Accounts receivable, net		5,729			8,610
Prepaid expenses and other current assets		4,263			3,388
Inventory, net		7,113			6,281
Total current assets		65,915			36,456
Prepaid expenses and other current assets		5,518			5,756
Total current assets		62,919			67,315
Goodwill		20,123			20,123
Intangible assets, net		1312,~~709~~933			1413,~~873~~321
Right-of-use lease assets		~~367~~275			~~536~~318
Property and equipment, net		~~140~~88			~~215~~113
Restricted cash		40			40
Total assets	$	~~100~~96,~~294~~378		$	72101,~~243~~230
LIABILITIES AND SHAREHOLDERS’ DEFICIT
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current liabilities:
Accounts payable	$	2,~~314~~789		$	2,~~762~~278
Accrued expenses		114,~~720~~297			64,~~494~~866
Accrued payroll and related expenses		1,801			2,878
Accrued interest expense on deferred royalty obligation, current portion		5,957			5,163
Lease liabilities, current portion		160			204
Deferred revenue		2,849			2,849
Total current liabilities		15,995			12,338
Paycheck Protection Program loan		-			2,325
Deferred royalty obligation, net		124,487			124,437
Lease liabilities, current portion		156			154
Accrued interest expense on deferred royalty obligation, less current portion		23,489			19,111
Total current liabilities		16,048			17,635
Lease liabilities, less current portion		208			332
Deferred royalty obligation, net		124,519			124,503
Other noncurrent liabilities		4,523			4,112
Accrued interest expense on deferred royalty obligation, less current portion		25,262			24,590
Total liabilities		168,702			160,330
Lease liabilities, less current portion		120			164
Commitments and contingencies (Note 6)
Fair value of contingent value rights		923			1,076
Shareholders’ deficit:
Total liabilities		166,872			167,968
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,518,191 and 27,402,648 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively		3			3
Commitments and contingencies (Note 8)
Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at September 30, 2021 and December 31, 2020; and liquidation preference of $3,906 at September 30, 2021 and December 31, 2020		3,906			3,906
Stockholders’ deficit:
Additional paid-in capital		988,544			984,756
Common Stock, $0.0001 par value; 100,000,000 shares authorized, 25,663,667 and 26,783,544 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively		3			3
Accumulated deficit		(1,060,861	)		(1,076,752	)
Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at March 31, 2022 and December 31, 2021; and liquidation preference of $3,906 at March 31, 2022 and December 31, 2021		3,906			3,906
Total shareholders’ deficit		(68,408	)		(88,087	)
Additional paid-in capital		982,687			986,445
Total liabilities and shareholders’ deficit	$	100,294		$	72,243
Accumulated deficit		(1,057,090	)		(1,057,092	)
Total stockholders’ deficit		(70,494	)		(66,738	)
Total liabilities and stockholders’ deficit	$	96,378		$	101,230

See accompanying notes to the condensed consolidated financial statements.

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share amounts)

	Three Months Ended						~~Nine Months Ended~~
	September 30,						September 30,
	March 31,
	2021			2020			2021			2020
	2022			2021
Revenue
Net product sales	$	1110,~~781~~409		$	98,~~072~~637		$	~~31,477~~		$	~~22,468~~
License and other revenue		~~1,533~~16			-25,500			~~32,033~~			-
Total revenue		1310,~~314~~425			934,~~072~~137			~~63,510~~			~~22,468~~
Operating expenses
Cost of product sales		2,~~031~~165			2,~~489~~731			~~6,918~~			~~4,013~~
Cost of license and other revenue		~~841~~5			-3,600			~~4,441~~			-
Selling, general and administrative		810,~~632~~274			128,~~493~~755			~~26,383~~			~~29,322~~
Research and development		~~1,285~~27			31,~~617~~558			~~3,957~~			~~21,581~~
Total operating expenses		12,~~789~~471			1816,~~599~~644			~~41,699~~			~~54,916~~
Income (loss) from operations		525			(9,527	)		21,811			(32,448	)
(Loss) income from operations		(2,046	)		17,493
Other (expense) income
Other income (expense)
Interest expense		(2,~~729~~402	)		(2,~~526~~609	)		~~(8,010~~	)		~~(7,402~~	)
Interest income		-			12			2			234
Gain on forgiveness of Paycheck Protection Program loan		2,325			-
Other income—related party		-1,583			-			~~2,532~~			~~4,085~~
Other (expense) income		(25	)		281			(395	)		(412	)
Other income (expense)		543			(448	)
Total other (expense) income, net		(2,754	)		(2,233	)		(5,871	)		(3,495	)
Total other income (expense), net		2,049			(3,057	)
Income (loss) before income taxes		(2,229	)		(11,760	)		15,940			(35,943	)
Income before income taxes		3			14,436
Provision for income taxes		311			-18			49			-
Net income (loss)	$	(2,260	)	$	(11,760	)	$	15,891		$	(35,943	)
Net income	$	2		$	14,418
Earnings (loss) per share
Earnings per share
Basic	$	(0.0800	)	$	(0.4353	)	$	~~0.58~~		$	~~(1.32~~	)
Diluted	$	(0.0800	)	$	(0.4342	)	$	~~0.46~~		$	~~(1.32~~	)
Shares used in computing earnings (loss) per share
Shares used in computing earnings per share
Basic		2726,~~497~~163			27,~~368~~427			~~27,462~~			~~27,311~~
Diluted		2732,~~497~~916			2734,~~368~~183			~~34,206~~			~~27,311~~

See accompanying notes to the condensed consolidated financial statements.

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Statements of ~~Shareholders~~Stockholders’ Deficit

(Unaudited)

(in thousands)

	Series C-12 Convertible Preferred Stock				Common Stock					Additional Paid-in			Accumulated			Total ~~Shareholders~~Stockholders’ ~~(Deficit)~~
	Shares		Amount		Shares			Amount		Capital			Deficit			~~Equity~~Deficit
Balance at December 31, 2020		4	$	3,906		27,403		$	3	$	984,756		$	(1,076,752	)	$	(88,087	)
Balance at December 31, 2021		4	$	3,906		26,784		$	3	$	986,445		$	(1,057,092	)	$	(66,738	)
Share-based compensation expense		-		-		-			-		1,~~116~~262			-			1,~~116~~262
Issuance of common stock under 2013 Equity Plan		-		-		29			-		154			-			154
Issuance of common stock under ESPP		-		-		42			-		159			-			159
Issuance of common stock under ESPP		-		-		17			-		81			-			81
Purchases of common stock under Stock Repurchase Plan		-		-		(1,162	)		-		(5,179	)		-			(5,179	)
Net income		-		-		-			-		-			~~14,418~~2			~~14,418~~2
Balance at March 31, 2021		4	$	3,906		27,449		$	3	$	986,107		$	(1,062,334	)	$	(72,318	)
Balance at March 31, 2022		4	$	3,906		25,664		$	3	$	982,687		$	(1,057,090	)	$	(70,494	)
Share-based compensation expense		-		-		-			-		1,024			-			1,024
Issuance of common stock under 2013 Equity Plan		-		-		-			-		1			-			1
Issuance of common stock under ESPP		-		-		33			-		117			-			117
Net income		-		-		-			-					3,733			3,733
Balance at June 30, 2021		4	$	3,906		27,482		$	3	$	987,249		$	(1,058,601	)	$	(67,443	)
Share-based compensation expense		-		-		-			-		1,175			-			1,175
Issuance of common stock under 2013 Equity Plan		-		-		-			-		1			-			1
Issuance of common stock under ESPP		-		-		36			-		119			-			119
Net loss		-		-		-			-		-			(2,260	)		(2,260	)
Balance at September 30, 2021		4	$	3,906		27,518		$	3	$	988,544		$	(1,060,861	)	$	(68,408	)

	Series C-1² Convertible Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Total Stockholders’
	Shares		Amount		Shares		Amount		Capital		Deficit			Deficit
Balance at December 31, 2020		4	$	3,906		27,403	$	3	$	984,756	$	(1,076,752	)	$	(88,087	)
Share-based compensation expense		-		-		-		-		1,116		-			1,116
Issuance of common stock under 2013 Equity Plan		-		-		29		-		154		-			154
Issuance of common stock under ESPP		-		-		17		-		81		-			81
Net income		-		-		-		-		-		14,418			14,418
Balance at March 31, 2021		4	$	3,906		27,449	$	3	$	986,107	$	(1,062,334	)	$	(72,318	)

	Series C-12 Convertible Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Total Shareholders’ (Deficit)
	Shares		Amount		Shares		Amount		Capital		Deficit			Equity
Balance at December 31, 2019		4	$	3,906		27,195	$	3	$	977,432	$	(1,037,331	)	$	(55,990	)
Share-based compensation expense		-		-		-		-		2,407		-			2,407
Issuance of common stock under 2013 Equity Plan		-		-		44		-		305		-			305
Issuance of common stock under ESPP		-		-		38		-		200		-			200
Net loss		-		-		-		-		-		(8,591	)		(8,591	)
Balance at March 31, 2020		4	$	3,906		27,277	$	3	$	980,344	$	(1,045,922	)	$	(61,669	)
Share-based compensation expense		-		-		-		-		1,590		-			1,590
Issuance of common stock under 2013 Equity Plan		-		-		50		-		300		-			300
Issuance of common stock under ESPP		-		-		32		-		159		-			159
Net loss		-		-		-		-		-		(15,592	)		(15,592	)
Balance at June 30, 2020		4	$	3,906		27,359	$	3	$	982,393	$	(1,061,514	)	$	(75,212	)
Share-based compensation expense		-		-		-		-		1,388					1,388
Issuance of common stock under 2013 Equity Plan		-		-		-		-		-					-
Issuance of common stock under ESPP		-		-		19		-		69					69
Net loss		-		-		-		-		-		(11,760	)		(11,760	)
Balance at September 30, 2020		4	$	3,906		27,378	$	3	$	983,850	$	(1,073,274	)	$	(85,515	)

See accompanying notes to the condensed consolidated financial statements.

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

	Nine Months Ended
	Three Months Ended
	September 30,
	March 31,
	2021			2020
	2022			2021
Operating activities
Net income (loss)	$	15,891		$	(35,943	)
Net income	$	2		$	14,418
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Share-based compensation expense		3,315			5,385
Non-cash interest expense		1,482			1,736
Depreciation expense		84			2,155
Share-based compensation expense		1,262			1,116
Non-cash interest expense		5,587			5,339
Amortization of intangible assets		388			388
Inventory fair value step-up adjustment included in cost of product sales		850			1,186
Amortization of right-of-use lease assets		43			46
Amortization of intangible assets		1,164			259
Depreciation expense		25			29
Loss on change in fair value of contingent value rights		395			-
Loss on short-term investments		309			-
Amortization of right-of-use lease assets		169			1,091
Gain on forgiveness of Paycheck Protection Program loan		(2,325	)		-
Loss on short-term investments		-			502
Gain on sale of non-controlling equity interest		(699	)		-
Loss on disposal of property and equipment, net of gain on lease termination		-			59
(Gain) loss on change in fair value of contingent value rights		(153	)		450
Inventory fair value step-up adjustment included in cost of product sales		-			850
Changes in operating assets and liabilities:
Accounts receivable, net		(2,~~959~~881	)		~~218~~1,681
Inventory, net		(~~931~~832	)		(~~1,482~~211	)
Prepaid expenses and other current assets		~~(875~~238	)		(2,~~445~~716	)
Accounts payable		~~(448~~511	)		(1,~~649~~664	)
Accrued expenses		~~4,083~~(569	)		(51,~~786~~101	)
Accrued payroll and related expenses		(1,077	)		(2,168	)
Lease liabilities		(42	)		(46	)
Lease liabilities		(168	)		(1,969	)
Net cash provided by operating activities		2,521			17,178
Net cash provided by (used for) operating activities		25,080			(30,358	)
Investing activities
Acquisition of Tetraphase, net of cash, cash equivalents and restricted cash acquired		-			(33,513	)
Net cash provided by (used for) investing activities		-			-
Proceeds from the sale of property and equipment		-			3,070
Purchases of property and equipment		(9	)		-
Proceeds from the sale of short-term investments		-			2,497
Purchases of short-term investments		-			(2,999	)
Net cash used for investing activities		(9	)		(30,945	)
Financing activities
Net proceeds from issuance of common stock under ESPP		317			428
Purchases of common stock under Stock Repurchase Plan		(5,179	)		-
Net proceeds from issuance of common stock under 2013 Equity Plan		156			605
Net proceeds from issuance of common stock under ESPP		159			81
Net cash provided by financing activities		473			1,033
Net proceeds from issuance of common stock under 2013 Equity Plan		-			154
Net increase (decrease) in cash, cash equivalents and restricted cash		25,544			(60,270	)
Net cash (used for) provided by financing activities		(5,020	)		235
Cash, cash equivalents and restricted cash, beginning of period		21,261			88,729
Net (decrease) increase in cash, cash equivalents and restricted cash		(2,499	)		17,413
Cash, cash equivalents and restricted cash, end of period	$	46,805		$	28,459
Cash, cash equivalents and restricted cash, beginning of period		46,708			21,261
Cash, cash equivalents and restricted cash, end of period	$	44,209		$	38,674
Supplemental disclosure of non-cash investing and financing activities
Sale of non-controlling equity interest	$	699		$	-
Forgiveness of Paycheck Protection Program loan	$	2,325		$	-
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	$	4644,~~765~~169		$	2738,~~760~~634
Restricted cash		40			~~699~~40
Total cash, cash equivalents and restricted cash	$	4644,~~805~~209		$	2838,~~459~~674

See accompanying notes to the condensed consolidated financial statements.

LA JOLLA PHARMACEUTICAL COMPANY

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

1. Business

La Jolla Pharmaceutical Company (collectively with its wholly owned subsidiaries, “La Jolla” or the “Company”) is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™® (angiotensin II) injection is approved by the U.S. Food and Drug Administration (“FDA”) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA™® (eravacycline) for injection is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older.

OnAs ~~July 28~~of March 31, ~~2020~~2022, La Jolla ~~completed~~had $44.6 ~~its acquisition~~ million of ~~Tetraphase Pharmaceuticals~~cash, ~~Inc.~~cash equivalents and ~~its~~short-term ~~subsidiaries~~investments ~~(“Tetraphase”),~~compared ato ~~biopharmaceutical~~$46.7 ~~company~~million ~~focused~~as onof ~~commercializing~~December ~~XERAVA~~31, ~~for~~2021. The $43 2.1 million decrease in ~~upfront~~cash, cash ~~plus~~equivalents ~~potential~~and ~~future~~short-term ~~cash~~investments ~~payments~~is ofprimarily updue to $16 2.5 million of net cash provided by operating activities, offset by $5.2 ~~The~~million in purchases of the Company’s ~~consolidated~~common ~~financial~~stock ~~results~~under ~~exclude~~its ~~Tetraphase~~stock repurchase plan. Based on the Company’s ~~financial~~current ~~results~~operating ~~prior~~plans toand projections, the ~~acquisition~~Company ~~closing~~expects ~~date~~that ofits ~~July~~existing 28cash, ~~2020~~cash ~~(see~~equivalents ~~Note~~and 11short-term investments will be sufficient to fund operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company expects to fund future operations with existing cash or cash generated from operations.

In January 2021, La Jolla and certain of its wholly owned subsidiaries entered into a license agreement with PAION AG to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland. Pursuant to the agreement: (i) the Company has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax; and (ii) the Company is entitled to receive potential commercial milestone payments of up to $109.5 million and royalties on net sales of GIAPREZA and XERAVA.

As of September 30, 2021 and December 31, 2020, the Company had cash and cash equivalents of $46.8 million and $21.2 million, respectively. Based on the Company’s current operating plans and projections, the Company expects that its existing cash and cash equivalents will be sufficient to fund operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company expects to fund future operations with existing cash or cash generated from operations.

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

The Company’s condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of SEC Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, ~~2020~~2021 included in the Company’s Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021, filed with the SEC on March 89, ~~2021~~2022 (the “Form 10-K”). The accompanying condensed consolidated financial statements include the accounts of La Jolla Pharmaceutical Company and its wholly owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation.

The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and the accompanying notes. Actual results may differ materially from these estimates. The results of operations for the three ~~and nine~~ months ended ~~September 30~~March 31, ~~2021~~2022 are not necessarily indicative of the results to be expected for the full year or any future interim or annual periods. The accompanying condensed consolidated balance sheet as of December 31, ~~2020~~2021 has been derived from the audited consolidated balance sheet as of December 31, ~~2020~~2021 contained in the Form 10-K.

Certain amounts previously reported in the financial statements have been reclassified to conform to the current year presentation. Such reclassifications did not affect net income, stockholders’ deficit or cash flows.

Summary of Significant Accounting Policies

During the ~~nine~~three months ended ~~September 30~~March 31, ~~2021~~2022, other than the ~~license~~short-term ~~and~~investments ~~other revenue recognition~~ policy described below, there have been no changes to the Company’s significant accounting policies as described in Note 2 of the Form 10-K.

6Short-term investments

Short-term investments are comprised of marketable equity securities and measured at fair value on a recurring basis in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 321, Investments—Equity Securities. Any unrealized gain (loss) is recorded in other income (expense), net. Marketable equity securities are classified as Level 1 in the ASC Topic 820-10, three-tier fair value hierarchy.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash. The Company maintains its cash in checking and savings accounts at federally insured financial institutions in excess of federally insured limits.

During the ~~nine~~three months ended ~~September 30~~March 31, ~~2021~~2022, ~~446~~287 hospitals in the U.S. purchased GIAPREZA~~. During the nine months ended September 30~~, ~~2021,~~and ~~808~~471 hospitals and other healthcare organizations in the U.S. purchased XERAVA. Hospitals and other healthcare organizations generally purchase our products through a network of specialty ~~and wholesale~~ distributors. These specialty ~~and wholesale~~ distributors are considered our customers for accounting purposes. The Company does not believe that the loss of one of these distributors would significantly impact the ability to distribute our products, as the Company expects that sales volume would be absorbed by the remaining distributors. The following table includes the percentage of U.S. net product sales and accounts receivable balances for the Company’s three major customers, each of which comprised 10% or more of its U.S. net product sales:

	U.S. Net Product Sales				Accounts Receivable			~~Accounts Receivable~~
	Three Months Ended September 30, 2021			Nine Months Ended September 30, 2021				As of September 30, 2021
	Three Months Ended March 31, 2022				As of March 31, 2022
Customer A		2836	%		33	%44	%		34	%
Customer B		3428	%		34	%29	%		33	%
Customer C		2629	%		26	%24	%		19	%
Total		8893	%		93	%97	%		86	%

Business Combinations

The Company accounts for business combinations using the acquisition method pursuant to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 805. This method requires, among other things, that results of operations of acquired companies are included in La Jolla’s financial results beginning on the respective acquisition dates, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Any excess of the fair value of consideration transferred (the “Purchase Price”) over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized as part of the Purchase Price at the estimated fair value on the acquisition date. Subsequent changes to the fair value of contingent consideration liabilities will be included in other (expense) income, net in the consolidated statements of operations. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.

Intangible Assets

Intangible assets acquired in a business combination are initially recorded at fair value. Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. Intangible assets with an indefinite useful life are not amortized.

The Company reviews its intangible assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If such circumstances are determined to exist, an estimate of undiscounted future cash flows produced by the asset, including its eventual residual value, is compared to the carrying value to determine whether impairment exists. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Fair value is estimated through discounted cash flow models to project cash flows from the asset.

The Company recognized no impairment charge for the nine months ended September 30, 2021.

Goodwill

Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized.

The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill.

The Company recognized no impairment charge for the nine months ended September 30, 2021.

Revenue Recognition

Pursuant to FASB ASC Topic 606—Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when its customers obtain control of the Company’s product, which typically occurs on delivery. Revenue is recognized in an amount that reflects the consideration that the Company expects to receive in exchange for those goods. To determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following 5 steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies the relevant performance obligations.

Product Sales

Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns, ~~Medicaid~~ rebates and administrative fees. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary materially from the Company’s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items include:

•

Chargebacks—Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers.

•

Discounts—The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers.

•

Returns—The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers.

• Medicaid Rebates—We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. The estimates for rebates are recorded as a reduction of revenue on delivery to the Company’s customers.6

•

Rebates—We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state’s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, the Company may offer customers incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to the Company’s customers.

•

Administrative Fees—The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency. Administrative fees are recorded as a reduction of revenue on delivery to customers.

The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly.

License and Other Revenue

We enter into out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development and regulatory milestone payments; and/or (iii) sales-based royalties and milestones.

If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from nonrefundable, upfront fees allocated to the license when the license is transferred to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of progress and related revenue recognition.

At the inception of each arrangement that ~~include~~includes milestone and other payments, other than sales-based milestone payments and nonrefundable, upfront license fees, we evaluate whether achieving each milestone payment or other payment is considered probable and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators or where attainment of the specified event is dependent on the development activities of a third party, are not considered probable of being achieved until those approvals are received or the specified event occurs.

For arrangements that include sales-based royalties and milestone payments, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of: (i) when the related sales occur; or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied.

We enter into commercial supply agreements with our out-licensees to supply our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases. The Company is considered the principal in these arrangements for accounting purposes as it controls the promised goods before transferring these goods to the out-licensee. The Company recognizes revenue when out-licensees obtain control of the Company’s product, which typically occurs on delivery.

Recent Accounting Pronouncements

The Company has considered all recently issued accounting pronouncements and has concluded that there are no recently issued accounting pronouncements that may have a material impact on its results of operations, financial condition or cash flows based on current information.

~~3. Earnings (Loss) per Share~~7

Basic earnings (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of potential common shares3. Earnings ~~Diluted earnings (loss)~~ per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding plus potential common shares. Convertible preferred stock and stock options are considered potential common shares and are included in the calculation of diluted earnings (loss) per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted earnings (loss) per share when their effect is anti-dilutive. For the three months ended September 30, 2021, there were 6.7 million of potential common shares that were excluded from the calculation of diluted loss per share because their effect was anti-dilutive. For the nine months ended September 30, 2021, there were 6.7 million potential common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 6.7 million shares of common stock issuable upon conversion of existing convertible preferred stock; and (ii) 9,000 stock options. For the three and nine months ended September 30, 2020, there were 10.0 million of potential common shares that were excluded from the calculation of diluted loss per share because their effect was anti-dilutive.Share

9Basic earnings per share is calculated by dividing net income by the weighted-average number of common shares outstanding during the period, without consideration of potential common shares. Diluted earnings per share is calculated by dividing net income by the weighted-average number of common shares outstanding plus potential common shares. Convertible preferred stock and stock options are considered potential common shares and are included in the calculation of diluted earnings per share using the if-converted method and treasury stock method, respectively, when their effect is dilutive. Potential common shares are excluded from the calculation of diluted earnings per share when their effect is anti-dilutive.

For the three months ended March 31, 2022, there were 6.8 million potential common shares that were included in the calculation of diluted earnings per share, which consists of: (i) 6.7 million shares of common stock issuable upon conversion of existing convertible preferred stock; and (ii) 18,000 stock options. For the three months ended March 31, 2022 and 2021, there were 6.4 million and 4.1 million, respectively, of potential common shares that were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive.

4. Balance Sheet Details

Restricted Cash

Restricted cash as of ~~September~~March 3031, ~~2021~~2022 and December 31, ~~2020~~2021 consisted of a $40,000 security deposit for the Company’s corporate purchasing credit card.

Inventory, Net

Inventory, net consisted of the following (in thousands):

	September 30,		December 31,
	March 31,		December 31,
	2021		2020
	2022		2021
Raw materials	$	~~802~~1,159	$	802
Work-in-process		4,~~253~~069		3,~~213~~844
Finished goods		1,~~039~~885		1,~~998~~635
Total inventory, net	$	67,~~094~~113	$	6,~~013~~281

As of ~~September 30, 2021 and December~~ March 31, ~~2020,~~2022 ~~inventory, net included zero~~ and ~~$0.9 million, respectively, of the fair value step-up adjustment to Tetraphase’s inventory recorded in connection with the acquisition of Tetraphase (see Note 11). As of September 30, 2021 and~~ December 31, ~~2020~~2021, total inventory is recorded net of inventory reserves of $1.30 million and $0.98 million, respectively.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following (in thousands):

	September 30,		December 31,
	March 31,		December 31,
	2021		2020
	2022		2021
Refundable withholding tax	$	3,375	$	-3,375
Prepaid clinical costs		188		820
Prepaid insurance		359		473
Prepaid manufacturing costs		76		930
Prepaid clinical costs		188		188
Prepaid insurance		28		505
Prepaid manufacturing costs		113		113
Other prepaid expenses and current assets		~~596~~1,483		1,~~133~~607
Total prepaid expenses and other current assets	$	45,~~263~~518	$	35,~~388~~756

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	September 30,			December 31,
	March 31,			December 31,
	2021			2020
	2022			2021
Computer hardware	$	319		$	~~310~~319
Furniture and fixtures		309			309
Software		203			~~733~~203
Total property and equipment, gross		831			~~1,352~~831
Accumulated depreciation and amortization		(~~691~~743	)		(~~1,137~~718	)
Total property and equipment, net	$	~~140~~88		$	~~215~~113

Intangible Assets, Net

Intangible assets, net consisted of the following (in thousands):

	Useful Life	~~September~~March 3031,			December 31,
	(years)	~~2021~~2022			~~2020~~2021
Technology	10	$	14,000		$	14,000
Trade name	10		1,520			1,520
Total intangible assets, gross			15,520			15,520
Accumulated amortization			(12,~~811~~587	)		(~~647~~2,199	)
Total intangible assets, net		$	1312,~~709~~933		$	1413,~~873~~321

The ~~intangible assets were recorded in connection with the acquisition of Tetraphase (see Note 11). The~~ Company recorded amortization expense of $0.4 million ~~and~~for ~~$1.2~~each ~~million~~of ~~for~~ the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021,~~2022 ~~respectively~~and 2021. The ~~Company~~estimated ~~recorded~~aggregate amortization expense offor ~~$0.3~~each ~~million~~of ~~for~~ the ~~three~~5 ~~and~~succeeding ~~nine~~years ~~months~~is ~~ended~~$1.6 ~~September 30, 2020~~million.

Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	September 30,		December 31,
	March 31,		December 31,
	2021		2020
	2022		2021
Accrued interest expense on deferred royalty obligation, current portion	$	4,726	$	3,567
Accrued payroll and related expenses	$	1,000	$	1,991
Deferred revenue		2,976		188
Accrued royalties and in-license fees		1,204		1,299
Accrued royalties and in-license fees		1,283		685
Accrued professional fees		599		410
Accrued manufacturing costs		~~1,230~~236		~~627~~232
Accrued professional fees		436		660
Accrued other		1,258		934
Accrued other		1,069		767
Total accrued expenses	$	4,297	$	4,866
Total accrued expenses	$	11,720	$	6,494

~~Other~~5. Paycheck ~~Noncurrent~~Protection ~~Liabilities~~Program loan

~~Other~~On ~~noncurrent~~April ~~liabilities~~22, ~~consisted~~2020, ofthe Company entered into a promissory note for $2.3 million under the ~~following~~Paycheck Protection Program (the “PPP Loan”). On March 22, 2022, the U.S. Small Business Administration notified the Company that 100% of the outstanding principal and accrued interest on the PPP Loan had been forgiven. As a result, the Company recorded a $2.3 million gain on forgiveness of the PPP Loan in ~~thousands~~other income (expense):, net during the three months ended March 31, 2022.

	September 30,		December 31,
	2021		2020
Paycheck Protection Program loan	$	2,318	$	2,302
Fair value of contingent value rights (see Note 11)		2,205		1,810
Total other noncurrent liabilities	$	4,523	$	4,112

~~On April 22, 2020, Tetraphase entered into a promissory note for $2~~6.~~3 million~~ ~~under~~Contingent ~~the~~Value Paycheck Protection Program (the “PPP Loan”). The interest rate on the PPP Loan is 1.0% per annum. The PPP Loan is unsecured and guaranteed by the U.S. Small Business Administration (the “SBA”). The principal amount of the PPP Loan may be forgiven under the Paycheck Protection Program, subject to certain requirements and to the extent that the PPP Loan proceeds are used to pay permitted expenses, including certain payroll, rent and utility payments. The Company applied for 100% forgiveness of the PPP Loan with the SBA on October 5, 2021. The Company will be obligated to make monthly payments of principal and interest with respect to any unforgiven portion of the PPP Loan by April 22, 2022. The obligation to repay the PPP Loan may be accelerated upon the occurrence of an event of default.Rights

On July 28, 2020, La Jolla completed its acquisition of Tetraphase Pharmaceuticals, Inc. and its subsidiaries (“Tetraphase”), a biopharmaceutical company focused on commercializing XERAVA, for $43 million in upfront cash plus potential future cash payments pursuant to contingent value rights (“CVRs”). As of March 31, 2022 and December 31, 2021, the holders of the CVRs are entitled to receive potential future cash payments of up to $13.5 million in the aggregate upon the achievement of certain net sales of XERAVA in the U. ~~Deferred~~S. ~~Royalty~~as ~~Obligation~~follows: (i) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (ii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024.

In ~~May~~connection ~~2018, the Company closed a $125.0 million royalty financing agreement (the “Royalty Agreement”)~~ with ~~HealthCare~~La ~~Royalty~~Jolla’s ~~Partners~~purchase ~~(“HCR”).~~price ~~Under~~allocation ~~the~~as ~~terms~~ of the ~~Royalty~~acquisition ~~Agreement~~date, ~~the~~La ~~Company~~Jolla ~~received~~recorded ~~$125.0~~a ~~million~~liability inequal ~~exchange~~to ~~for~~the ~~tiered~~estimated ~~royalty~~fair ~~payments~~value ~~on worldwide net sales~~ of ~~GIAPREZA.~~future ~~HCR~~cash ispayments ~~entitled~~pursuant to ~~receive~~the ~~quarterly~~CVRs ~~royalties~~based on ~~worldwide~~a ~~net~~Monte ~~sales~~Carlo ~~of GIAPREZA beginning April 1, 2018~~simulation. ~~Quarterly~~The ~~payments~~CVRs toare ~~HCR~~measured ~~under~~at ~~the~~fair ~~Royalty~~value ~~Agreement~~on ~~start at~~ a ~~maximum~~recurring ~~royalty rate~~basis, ~~with~~and ~~step-downs~~any ~~based~~gain on(loss) ~~the~~resulting ~~achievement~~from ofthe ~~annual~~change ~~net~~in ~~product~~fair ~~sales~~value ~~thresholds.~~of ~~Through~~CVRs ~~December~~are ~~31,~~recorded ~~2021,~~in ~~the~~other ~~royalty~~income ~~rate~~(expense), ~~will~~net. beThe aCVRs ~~maximum~~are ofclassified ~~10%.~~as ~~Starting~~Level ~~January~~3 1,in ~~2022,~~ the ~~maximum~~ASC ~~royalty~~Topic ~~rate~~820-10 ~~may increase by 4% if an agreed~~three-~~upon,~~tier ~~cumulative~~fair ~~net~~value ~~product sales threshold~~ hierarchy.

11As of March 31, 2022 and December 31, 2021, the fair value of the CVRs was $0.9 million and $1.1 million, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded a gain (loss) resulting from the change in fair value of CVRs of $0.2 million and $(0.5) million, respectively.

~~has not been met, and, starting January 1, 2024, the maximum royalty rate may increase by an additional 4% if a different agreed-upon, cumulative net product sales threshold has not been met~~7. Deferred ~~The~~ Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million. The Royalty Agreement expires upon the first to occur of January 1, 2031 or when the maximum aggregate royalty payments have been made. The Royalty Agreement was entered into by the Company’s wholly owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the Royalty Agreement against La Jolla Pharmaceutical Company or any assets other than GIAPREZA.Obligation

OnIn ~~receipt~~May ~~of the $125.0 million payment from HCR~~2018, the Company ~~recorded~~closed a ~~deferred royalty obligation of~~ $125.0 million, ~~net~~royalty offinancing ~~issuance~~agreement ~~costs of $0.7 million. For~~ (the ~~three~~“Royalty ~~and~~Agreement”) ~~nine~~with ~~months~~HealthCare ~~ended~~Royalty ~~September~~Partners ~~30,~~(“HCR”). ~~2021,~~Under the ~~Company~~terms ~~recognized interest expense, including amortization~~ of the ~~obligation~~Royalty ~~discount~~Agreement, ofthe ~~$2.7~~Company ~~million~~received ~~and~~ $8125.0 million, ~~respectively.~~in ~~For~~exchange ~~the~~for ~~three~~tiered ~~and~~royalty ~~nine~~payments ~~months~~on ~~ended~~worldwide ~~September~~net ~~30,~~sales ~~2020,~~of ~~the~~GIAPREZA. ~~Company~~HCR ~~recognized~~is ~~interest~~entitled ~~expense,~~to ~~including~~receive ~~amortization~~quarterly ofroyalties ~~the~~on ~~obligation~~worldwide ~~discount,~~net sales of ~~$2.5~~GIAPREZA ~~million~~beginning ~~and~~April ~~$7.4 million~~1, ~~respectively~~2018. ~~The~~Quarterly ~~carrying~~payments ~~value~~to ofHCR under the ~~deferred~~Royalty ~~royalty~~Agreement ~~obligation~~start asat ~~of September~~a ~~30,~~maximum ~~2021~~royalty ~~and December 31~~rate, ~~2020~~with ~~was $124.5~~step-downs ~~million~~based ~~and~~on ~~$124.4~~the ~~million,~~achievement ~~respectively, net~~ of ~~unamortized~~annual ~~obligation~~net ~~discount~~product ofsales $0thresholds.5 ~~million~~Through ~~and~~December ~~$0.6 million~~31, ~~respectively~~2021, ~~and~~the ~~was~~maximum ~~classified~~royalty asrate awas ~~noncurrent liability~~10%. ~~The~~Starting ~~related~~January ~~accrued~~1, ~~interest~~2022, ~~expense~~the asmaximum ofroyalty ~~September~~rate ~~30,~~increased ~~2021~~by ~~and December 31~~4%, ~~2020 was $28.2 million~~ and ~~$22.7~~starting ~~million~~January 1, ~~respectively~~2024, ofthe ~~which~~maximum ~~$23.5~~royalty ~~million~~rate ~~and~~may ~~$19.1~~increase ~~million~~by ~~was~~an ~~classified~~additional as4%, ~~noncurrent~~if ~~liabilities~~an agreed-upon, ~~respectively.~~cumulative ~~During~~net ~~the~~product ~~three~~sales ~~and~~threshold ~~nine~~has ~~months~~not ~~ended~~been ~~September~~met. ~~30,~~The ~~2021,~~Royalty ~~the~~Agreement ~~Company~~is ~~made~~subject to maximum aggregate royalty payments to HCR of $0225.90 million. ~~and~~The ~~$2.4~~Royalty ~~million,~~Agreement ~~respectively.~~expires Asupon ofthe ~~September~~first ~~30,~~to ~~2021~~occur ~~and~~of ~~December~~January 311, ~~2020,~~2031 or when the ~~Company~~maximum ~~recorded~~aggregate royalty ~~obligations~~payments ~~payable~~have ofbeen $0made.9 ~~million~~The ~~and~~Royalty ~~$0.9~~Agreement ~~million,~~was ~~respectively,~~entered ininto ~~accrued~~by ~~expenses.~~the ~~The~~Company’s ~~deferred~~wholly ~~royalty~~owned ~~obligation~~subsidiary, isLa ~~classified~~Jolla asPharma, ~~Level~~LLC, 3and inHCR ~~the~~has ~~FASB~~no ~~ASC~~recourse ~~Topic~~under ~~820-10,~~the ~~three-tier~~Royalty ~~fair~~Agreement ~~value~~against ~~hierarchy,~~La ~~and~~Jolla ~~its~~Pharmaceutical ~~carrying~~Company ~~value~~or ~~approximates~~any ~~fair~~assets ~~value~~other than GIAPREZA.

~~Under~~On ~~the~~receipt ~~terms~~ of the ~~Royalty~~$125.0 ~~Agreement,~~million Lapayment ~~Jolla~~from ~~Pharma~~HCR, ~~LLC~~the ~~has~~Company ~~certain~~recorded ~~obligations,~~a ~~including~~deferred ~~the~~royalty obligation toof ~~use~~$125.0 ~~commercially~~million, ~~reasonable~~net ~~and~~of ~~diligent~~issuance ~~efforts~~costs toof ~~commercialize~~$0.7 ~~GIAPREZA~~million. IfFor Lathe ~~Jolla~~three ~~Pharma,~~months ~~LLC~~ended isMarch 31, ~~held~~2022 toand ~~not have met these obligations~~2021, ~~HCR would have~~ the ~~right~~Company torecognized ~~terminate~~interest ~~the~~expense, ~~Royalty~~including ~~Agreement~~amortization ~~and~~of ~~demand~~the ~~payment~~obligation ~~from La Jolla Pharma~~discount, ~~LLC~~ of ~~either~~ $~~125~~2.04 million orand $~~225~~2.06 million ~~(depending~~, onrespectively. ~~which~~The ~~obligation~~carrying Lavalue ~~Jolla~~of ~~Pharma,~~the ~~LLC~~deferred isroyalty ~~held~~obligation toas ~~not have met)~~of March 31, ~~minus~~2022 ~~aggregate~~and ~~royalties~~December ~~already~~31, ~~paid~~2021 ~~to HCR~~was $124.5 ~~In the event that La Jolla Pharma~~million, ~~LLC~~net ~~fails~~of tounamortized ~~timely~~obligation ~~pay~~discount ~~such~~of ~~amount~~$0.5 ~~if and when due~~million, ~~HCR~~which ~~would~~was ~~have~~classified ~~the~~as ~~right~~a tononcurrent ~~foreclose on the GIAPREZA-related assets~~liability. The ~~Company~~related ~~concluded~~accrued ~~that~~interest ~~certain~~expense ofas ~~these contract provisions that could result in an acceleration~~ of ~~amounts~~March 31, ~~due~~2022 ~~under~~and ~~the~~December 31, ~~Royalty~~2021 ~~Agreement~~was ~~are~~$31.2 ~~embedded~~million ~~derivatives~~and ~~that~~$29.8 ~~require~~million, ~~bifurcation~~respectively, ~~from~~of ~~the~~which ~~deferred~~$25.3 ~~royalty~~million ~~obligation~~ and ~~fair value recognition~~$24.6 ~~The~~million ~~Company~~was ~~determined~~classified ~~the~~as ~~fair~~noncurrent ~~value~~liabilities, ofrespectively. During each ~~derivative~~of ~~by assessing~~ the ~~probability~~three ofmonths ~~each~~ended ~~event occurring~~March 31, as2022 ~~well as the potential repayment amounts~~ and ~~timing of such repayments that would result under various scenarios. As a result of this assessment~~2021, the Company ~~determined~~made ~~that~~royalty ~~the~~payments ~~fair~~to ~~value~~HCR of ~~the~~$0.9 ~~embedded~~million. ~~derivatives~~As ~~is immaterial as~~ of ~~September~~ 30March 31, ~~2021~~2022 and December 31, ~~2020. Each reporting period~~2021, the Company ~~estimates~~recorded ~~the~~royalty ~~fair~~obligations ~~value~~payable of ~~the~~$1.1 ~~embedded~~million ~~derivatives until the features lapse~~ and~~/or~~ ~~the~~$0.9 ~~termination~~million, ofrespectively, ~~the~~in ~~Royalty~~accrued ~~Agreement~~expenses. ~~Any~~The ~~material~~deferred ~~change~~royalty inobligation ~~the~~is ~~fair~~classified ~~value~~as ofLevel ~~the~~3 ~~embedded~~in ~~derivatives~~the ~~will~~FASB beASC ~~recorded~~Topic as820-10, ~~either~~three-tier afair ~~gain~~value orhierarchy, ~~loss~~and onits ~~the~~carrying ~~consolidated~~value ~~statements~~approximates offair ~~operations~~value.

6Under the terms of the Royalty Agreement, La Jolla Pharma, LLC has certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA. ~~Commitments~~ If La Jolla Pharma, LLC is held to not have met these obligations, HCR would have the right to terminate the Royalty Agreement and ~~Contingencies~~demand payment from La Jolla Pharma, LLC of either $125.0 million or $225.0 million (depending on which obligation La Jolla Pharma, LLC is held to not have met), minus aggregate royalties already paid to HCR. In the event that La Jolla Pharma, LLC fails to timely pay such amount if and when due, HCR would have the right to foreclose on the GIAPREZA-related assets. The Company concluded that certain of these contract provisions that could result in an acceleration of amounts due under the Royalty Agreement are embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. The Company determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, the

Company determined that the fair value of the embedded derivatives is immaterial as of March 31, 2022 and December 31, 2021. Each reporting period, the Company estimates the fair value of the embedded derivatives until the features lapse and/or the termination of the Royalty Agreement. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss on the condensed consolidated statements of operations.

8. Commitments and Contingencies

Lease Commitments

~~Future~~In ~~minimum~~December ~~lease~~2020, ~~payments~~the Company entered into a sublease agreement for office space in Waltham, ~~excluding~~Massachusetts (the “Waltham Sublease”). The Waltham Sublease commenced on December 21, 2020 and expires on November 30, 2023. In addition to rent of approximately $15,000 per month, the Waltham Sublease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises (collectively, “Lease Operating Costs”). The Waltham Sublease contains customary default provisions, representations, warranties and covenants. The Waltham Sublease is classified as an operating lease. The Company recognizes the Waltham Sublease expense in the condensed consolidated statements of ~~September~~operations ~~30,~~and ~~2021~~records ~~are~~a lease liability and right-of-use asset for this lease. The option to extend the Waltham Sublease was not recognized as ~~follows~~part ~~(in~~of ~~thousands):~~the Company’s lease liabilities and right-of-use lease assets.

2021	$	52
2022		181
2023		166
Thereafter		-
Total future minimum lease payments		399
Less: discount		(31	)
Total lease liabilities	$	368

Future minimum lease payments, excluding Lease Operating Costs, as of March 31, 2022 are as follows (in thousands):

2022	$	136
2023		166
Thereafter		-
Total future minimum lease payments		302
Less: discount		(26	)
Total lease liabilities	$	276

Lease expense under current and former leases was approximately $~~0.1~~45,000 ~~million~~ and $0.2 1 million for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021,~~2022 ~~respectively. Lease expense under former leases was approximately $0.7 million~~ and ~~$2.0 million for the three and nine months ended September 30~~2021, ~~2020,~~ respectively. Cash paid for amounts included in the measurement of lease liabilities was $3345,000 and $~~0.1~~50,000 ~~million~~ for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021,~~2022 ~~respectively. Cash paid for amounts included in the measurement of lease liabilities was $0.8~~ and ~~$2.8 million for the three and nine months ended September 30~~2021, ~~2020,~~ respectively. As of ~~September~~March 3031, ~~2021~~2022, the weighted-average remaining lease term and the weighted-average discount rate for the Company’s only operating lease, the Waltham Sublease, was 2.1.7 years and 3.43%, respectively.

~~Waltham~~Legal ~~Sublease~~Proceedings

InOn ~~December~~February ~~2020~~15, 2022, the Company ~~entered~~received ~~into~~ a ~~sublease~~paragraph ~~agreement~~IV ~~for~~notice ~~office~~of ~~space~~certification ~~in Waltham, Massachusetts~~ (the “~~Waltham~~Notice ~~Sublease~~Letter”). ~~The~~from ~~Waltham~~Gland ~~Sublease~~Pharma ~~commenced~~Limited on(“Gland”) ~~December~~advising ~~21,~~that ~~2020~~Gland ~~and~~had ~~expires~~submitted onan ~~November~~Abbreviated ~~30,~~New ~~2023.~~Drug InApplication ~~addition~~(“ANDA”) to ~~rent~~the ofFDA ~~approximately~~seeking ~~$15,000~~approval ~~per~~to ~~month~~manufacture, ~~the~~use ~~Waltham~~or ~~Sublease~~sell ~~requires~~a ~~the~~generic ~~Company~~version toof ~~pay~~GIAPREZA® ~~certain~~in ~~taxes,~~the ~~insurance~~U.S. ~~and~~prior ~~operating~~to ~~costs~~the ~~relating~~expiration toof ~~the~~U.S. ~~leased~~Patent ~~premises~~Nos.: ~~(collectively~~9,220,745; ~~“Lease~~9,572,856; ~~Operating~~9,867,863; ~~Costs”).~~10,028,995; ~~The~~10,335,451; ~~Waltham~~10,493,124; ~~Sublease~~10,500,247; ~~contains~~10,548,943; ~~customary~~11,096,983; ~~default~~and ~~provisions~~11,219,662 ~~representations~~(the “GIAPREZA Patents”), ~~warranties~~which ~~and~~are ~~covenants.~~listed ~~The~~in ~~Waltham~~the ~~Sublease~~FDA’s isApproved ~~classified~~Drug asProducts anwith ~~operating~~Therapeutic ~~lease~~Equivalence Evaluations (the “Orange Book”). The ~~Company~~Notice ~~recognizes~~Letter alleges that the ~~Waltham~~GIAPREZA ~~Sublease~~Patents ~~expense~~are ininvalid, ~~the~~unenforceable ~~consolidated~~and/or ~~statements~~will ofnot ~~operations~~be ~~and~~infringed ~~records~~by athe ~~lease~~commercial ~~liability~~manufacture, ~~and~~use ~~right-~~or sale of~~-use~~ ~~asset~~the ~~for~~generic ~~this~~product ~~lease~~described in Gland’s ANDA.

~~San~~On ~~Diego~~March ~~Sublease~~29, 2022, the Company filed a complaint for patent infringement of the GIAPREZA Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland’s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA is a new chemical entity and the Company filed a complaint for patent infringement within 45 days of receipt of the Notice Letter, the FDA cannot approve Gland’s ANDA any earlier than 7.5 years from the approval of the GIAPREZA NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed. The Company intends to vigorously enforce its intellectual property rights relating to GIAPREZA.

In September 2020, the Company entered into a sublease agreement for office space in San Diego, California with an entity of which the Chairman of the Company’s board of directors is also the chairman and chief executive officer (the “San Diego Sublease”). The San Diego Sublease term is approximately 7 years, and the rent is approximately $12,000 per month. The San Diego Sublease is cancellable without penalty by either party with 30-days’ written notice. The San Diego Sublease is a short-term lease for accounting purposes. The Company made payments of approximately $42,000 and $0.1 million under the San Diego Sublease during the three and nine months ended September 30, 2021. The Company recognizes the San Diego Sublease payments in the consolidated statements of operations and does not record a lease liability or right-of-use asset for this lease.11

~~Contingencies~~9. Stockholders’ Deficit

From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation.

7. Shareholders’ Equity

Preferred Stock

As of ~~September 30~~March 31, ~~2021~~2022 and December 31, ~~2020~~2021, 3,906 shares of Series C-12 Convertible Preferred Stock (“Series C-12 Preferred”) were issued and outstanding, and convertible into 6,735,378 shares of common stock. As of ~~September~~March 3031, ~~2021~~2022 and December 31, ~~2020~~2021, the Series C-12 Preferred liquidation preference was approximately $3.9 million. The Series C-12 Preferred does not pay a dividend. The holders of the Series C-12 Preferred do not have voting rights, other than for general protective rights required by the Delaware General Corporation Law.

~~8. Equity~~Stock ~~Incentive~~Repurchase ~~Plans~~Plan

On November 17, 2021, the Company announced that it would commence a stock repurchase plan for up to $10 million of the Company’s common stock. On March 7, 2022, the Board approved a $5 million increase to the stock repurchase plan from up to $10 million to up to $15 million of the Company’s common stock. The plan has no time limit and can be discontinued at any time. For the three months ended March 31, 2022, the Company repurchased approximately 1.2 million shares of its common stock for $5.2 million, including commissions.

10. Equity Incentive Plans

2013 Equity Incentive Plan

A total of 9,600,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2013 Equity Incentive Plan (the “2013 Equity Plan”). As of ~~September 30~~March 31, ~~2021~~2022 and December 31, ~~2020~~2021, 53,~~462~~167,~~486~~189 and 5,~~478~~503,~~334~~796 shares of common stock, respectively, remained available for future grants under the 2013 Equity Plan.

2018 Employee Stock Purchase Plan

A total of 750,000 shares of common stock have been reserved for issuance under the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan (the “ESPP”). As of ~~September 30~~March 31, ~~2021~~2022 and December 31, ~~2020~~2021, ~~369~~293,~~902~~412 and ~~455~~335,~~768~~473 shares of common stock, respectively, remained available for future grants under the ESPP.

Equity Awards

The activity related to equity awards, which are comprised of stock options, during the ~~nine~~three months ended ~~September 30~~March 31, ~~2021~~2022 is summarized as follows:

	Equity Awards			Weighted- average Exercise Price per Share		Weighted- average Remaining Contractual Term(1) (years)		Aggregate Intrinsic Value(2) (millions)
Outstanding at December 31, 2020		4,121,666		$	8.67
Outstanding at December 31, 2021		4,096,204		$	7.22
Granted		~~876~~2,~~991~~427,605		$	4.6678
Exercised		~~(29,677~~-	)	$	~~5.21~~-
Cancelled/forfeited		(~~831~~90,~~466~~998	)	$	105.0086
Outstanding at September 30, 2021		4,137,514		$	7.56		8.3	$	0.1
Outstanding at March 31, 2022		6,432,811		$	6.32		8.6	$	0.3
Exercisable at September 30, 2021		1,191,395		$	14.61		6.3	$	-
Exercisable at March 31, 2022		1,940,093		$	10.13		6.9	$	0.1

⁽¹⁾Represents the weighted-average remaining contractual term of stock options.

(2) Aggregate intrinsic value represents the product of the number of equity awards outstanding or equity awards exercisable multiplied by the difference between the Company’s closing stock price per share on the last trading day of the period, which was $34.9927 as of ~~September~~March 3031, ~~2021~~2022, and the exercise price.

Share-based Compensation Expense

The classification of share-based compensation expense is summarized as follows (in thousands):

	Three Months Ended				~~Nine Months Ended~~
	September 30,				September 30,
	March 31,
	2021		2020		2021		2020
	2022		2021
Selling, general and administrative	$	~~894~~1,245	$	~~697~~840	$	~~2,711~~	$	~~2,167~~
Research and development		~~281~~17		~~691~~276		~~604~~		~~3,218~~
Total share-based compensation expense	$	1,~~175~~262	$	1,~~388~~116	$	~~3,315~~	$	~~5,385~~

As of ~~September 30~~March 31, ~~2021~~2022, total unrecognized share-based compensation expense related to unvested equity awards was $814.2 million, which is expected to be recognized over a weighted-average period of 3.02 years. As of ~~September 30~~March 31, ~~2021~~2022, there was no unrecognized share-based compensation expense related to shares of common stock issued under the ESPP.

911. Other Income—Related Party

The Company ~~has~~owns a non-voting ~~profits~~ interest in a related party, which provides the Company with the potential to receive a portion of the future distributions of ~~profits~~free cash flow, if any. Investment funds affiliated with the Chairman of the Company’s board of directors have a controlling interest in the related party. During the three ~~and nine~~ months ended ~~September 30~~March 31, ~~2021~~2022, the Company received distributions of ~~zero and~~ $21.56 million, ~~respectively,~~ in connection with this ~~profits~~ interest. During the three ~~and nine~~ months ended ~~September~~ 30March 31, ~~2020~~2021, the Company ~~received~~did ~~distributions~~not ofreceive ~~zero~~any ~~and $4.1 million,~~distributions ~~respectively,~~ in connection with this ~~profits~~ interest.

1012. License Agreements

In-license Agreements

George Washington University

In December 2014, the Company entered into a patent license agreement with George Washington University (“GW”), which was subsequently amended and restated (the “GW License”) and assigned to La Jolla Pharma, LLC. Pursuant to the GW License, GW exclusively licensed to the Company certain intellectual property rights relating to GIAPREZA, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA. Under the GW License, La Jolla Pharma, LLC is obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA. The Company has paid a one-time license initiation fee, annual maintenance fees, an amendment fee, additional payments following the achievement of certain development and regulatory milestones and royalties. ~~As a result of the European Commission’s approval of GIAPREZA in August 2019, the Company made a milestone payment to GW in the amount of $0.5 million in the first quarter of 2020.~~ The Company is obligated to pay a 6% royalty on net sales of GIAPREZA and 15% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering GIAPREZA. During the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021,~~2022 ~~the Company made payments to GW of $0.5 million~~ and ~~$3.7 million~~2021, ~~respectively. During~~ the ~~three and nine months ended September 30, 2020, the~~ Company made payments to GW of $0.36 million and $1.2.8 million, respectively.

Harvard University

In August 2006, the Company entered into a license agreement with Harvard University (“Harvard”), which was subsequently amended and restated (the “Harvard License”). Pursuant to the Harvard License, Harvard exclusively licensed to the Company certain intellectual property rights relating to tetracycline-based products, including XERAVA, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, the Company is obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA. For each product covered by the Harvard License, the Company is obligated to make certain payments for the following: (i) up to approximately $15.1 million upon the achievement of certain clinical development and regulatory milestones; (ii) a 5% royalty on direct U.S. net sales of XERAVA; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA, starting at a minimum royalty rate of 4.5%, with step-ups to a maximum royalty of 7.5% based on the achievement of annual net product sales thresholds; and (iv) 20% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA. During each of the three ~~and nine~~ months ended ~~September 30~~March 31, ~~2021,~~2022 ~~the Company made royalty payments to Harvard of $0.1 million~~ and ~~$1.7 million~~2021, ~~respectively, none of which related to clinical development and regulatory milestones. Subsequent to July 28, 2020 and through September 30, 2020,~~ the Company made ~~royalty~~ payments to Harvard of $0.1 million, none of which related to clinical development and regulatory milestones.

Paratek Pharmaceuticals, Inc.

In March 2019, the Company entered into a license agreement with Paratek Pharmaceuticals, Inc. (“Paratek”), which was subsequently amended and restated (the “Paratek License”). Pursuant to the Paratek License, Paratek non-exclusively licensed to the Company certain intellectual property rights relating to XERAVA, including non-exclusive rights to certain issued patents and patent applications covering XERAVA. The Company is obligated to pay Paratek a 2.25% royalty based on direct U.S. net sales of XERAVA. The Company’s obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA and shall continue until there are no longer any valid claims of the Paratek patents, which will expire in October 2023. During the three and nine months ended September 30, 2021, the Company made royalty payments to Paratek of $0.1 million. Subsequent to July 28, 2020 and through September 30, 2020, the Company made royalty payments to Paratek of $33,000.

non-exclusively licensed to the Company certain intellectual property rights relating to XERAVA, including non-exclusive rights to certain issued patents and patent applications covering XERAVA. The Company is obligated to pay Paratek a 2.25% royalty based on direct U.S. net sales of XERAVA. The Company’s obligation to pay royalties with respect to the licensed product is retroactive to the date of the first commercial sale of XERAVA and shall continue until there are no longer any valid claims of the Paratek patents, which will expire in October 2023. During each of the three months ended March 31, 2022 and 2021, the Company made royalty payments to Paratek of $0.1 million.

Out-license Agreements

PAION AG

OnIn January ~~12,~~ 2021, La Jolla Pharmaceutical Company and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC and Tetraphase Pharmaceuticals, Inc., entered into an exclusive license agreement (the “PAION License”) with PAION AG and its wholly owned subsidiary (collectively, “PAION”). Pursuant to the PAION License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland (collectively, the “PAION Territory”). La Jolla has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax, and is entitled to receive potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments. La Jolla recognized the upfront cash payment of $22.5 million as license and other revenue for the three months ended March 31, 2021, and the 15% refundable withholding tax of $3.4 million was recorded as an other current asset as of March 31, 2022 and December 31, 2021. In addition, royalties payable under the PAION License will be subject to reduction on account of generic competition and after patent expiration in a jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA and XERAVA in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA and XERAVA in the PAION Territory. The Company has not received any payments from PAION related to either royalties or commercial milestones.

OnIn July ~~13,~~ 2021, the Company entered into a commercial supply agreement with PAION whereby the Company will supply PAION a minimum quantity of GIAPREZA and XERAVA through July 13, 2024. The supply agreement will automatically renew until the earlier of July 13, 2027, or until a new supply agreement is executed. During the initial 3-year term of the supply agreement, the Company will be reimbursed for direct and certain indirect manufacturing costs at cost.

Everest Medicines Limited

In February 2018, the Company entered into a license agreement with Everest, which was subsequently amended and restated (the “Everest License”). Pursuant to the Everest License, the Company granted Everest an exclusive license to develop and commercialize XERAVA for the treatment of cIAI and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the “Everest Territory”). The Company is eligible to receive an additional $8.0 million regulatory milestone payment and up to an aggregate of $20.0 million in sales milestone payments. The Company is also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3iii) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory. In March 2021, the Company received a $3.0 million milestone payment associated with the submission of an NDA with the China National Medical Products Administration (“NMPA”) for XERAVA for the treatment of cIAI in patients in China. Amounts due under the Harvard License for this milestone payment were included as research and development expense on the condensed consolidated statements of operations. XERAVA was approved in Singapore by the Health Science Authority in April 2020.

In May 2021, the Company entered into a commercial supply agreement with Everest whereby the Company will supply Everest a minimum quantity of XERAVA through December 31, 2023 and will transfer to Everest certain XERAVA-related manufacturing know-how. Pursuant to the supply agreement: (i) the Company ~~has~~ received $6.8 million of upfront payments during the year ended December 31, 2021 comprised of: (1) a $4.0 million upfront technology transfer payment; and (2) a $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022; (ii) the Company ~~will~~received ~~receive~~ an additional $1.0 million technology transfer payment byin January 30, 2022; and (iii) the Company will be reimbursed for direct and certain indirect manufacturing costs at 110% of costs through December 31, 2023. The Company recognized the $5.0 million of technology transfer-related payments as license and other revenue during the nine months ended September 30, 2021 as Everest obtained control of the XERAVA-related manufacturing know-how prior to September 30, 2021. The Company recognized the $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022 as deferred revenue as of September 30, 2021 as the performance obligation to deliver XERAVA has not yet been satisfied.

~~11. Acquisition of Tetraphase Pharmaceuticals, Inc.~~14

~~On June 24, 2020, La Jolla entered into an Agreement and Plan~~ of ~~Merger~~cost ~~with~~through ~~Tetraphase,~~December ~~a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life‑threatening infections~~31, ~~and TTP Merger Sub, Inc~~2023., aThe ~~wholly~~Company ~~owned~~recognized ~~subsidiary~~the ~~of La Jolla~~$5.0 Onmillion ~~July 28, 2020, La Jolla completed its acquisition~~ of ~~Tetraphase~~technology ~~for~~transfer-related ~~$43 million in upfront cash plus potential future cash~~ payments ofas uplicense toand ~~$16~~other ~~million~~revenue ~~pursuant~~during ~~to contingent value rights (“CVRs”). The holders of~~ the ~~CVRs~~year ~~are~~ended ~~entitled~~December to31, ~~receive~~2021 ~~potential~~as ~~future~~Everest ~~cash~~obtained ~~payments~~control of ~~up to $16 million in~~ the ~~aggregate~~XERAVA-related ~~upon~~manufacturing ~~the~~know-how ~~achievement~~prior ofto ~~certain~~December ~~net~~31, ~~sales~~2021. ofThe ~~XERAVA~~Company inrecognized the ~~U.S. as follows: (i)~~ $2.58 million ifpartial ~~2021~~prepayment ~~XERAVA~~for ~~U.S. net sales are at least $20 million; (ii) $4.5 million if~~ XERAVA ~~U.S.~~that ~~net~~is ~~sales~~expected ~~are~~to atbe ~~least~~delivered ~~$35~~to ~~million~~Everest during ~~any~~2022 ~~calendar~~as ~~year~~deferred ~~ending~~revenue onas orof ~~prior~~March ~~to December~~ 31, ~~2024;~~2022 and ~~(iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to~~ December 31, ~~2024.~~2021 ~~Following~~as the ~~acquisition,~~performance ~~Tetraphase~~obligation ~~became~~to adeliver ~~wholly~~XERAVA ~~owned~~had ~~subsidiary~~not ofyet Labeen ~~Jolla~~satisfied.

~~The acquisition of Tetraphase was accounted for as a business combination using the acquisition method pursuant to FASB ASC Topic 805~~13. Short-term As the acquirer for accounting purposes, La Jolla has estimated the Purchase Price, assets acquired and liabilities assumed as of the acquisition date, with the excess of the Purchase Price over the fair value of net assets acquired recognized as goodwill.Investments

~~The~~In ~~Purchase~~January ~~Price~~2022, isAcelRx ~~comprised~~Pharmaceuticals, ofInc. ~~the~~(“AcelRx”) ~~upfront~~closed ~~cash~~its acquisition of ~~$43~~Lowell ~~million~~Therapeutics, ~~and~~Inc. (“Lowell”), a privately held company in which La Jolla held an approximately 15% non-controlling equity interest. Through the ~~estimated~~closing ~~fair~~of ~~value~~the acquisition, La Jolla’s investment in Lowell was measured at its contributed cost of ~~potential~~zero ~~future~~in ~~cash~~the ~~payments~~consolidated balance sheets in accordance with the measurement alternative pursuant to ~~the~~FASB ~~CVRs~~ASC 321, Investments—Equity Securities. ~~The~~In ~~estimated~~connection ~~fair~~with ~~value~~AcelRx’s acquisition of ~~assets~~Lowell, ~~acquired~~La ~~was~~Jolla ~~$54~~received: (i) approximately 1.74 million, ~~and~~shares ~~the~~of ~~estimated~~AcelRx ~~fair~~common stock; and (ii) contingent value ofrights ~~liabilities~~(“AcelRx ~~assumed~~CVRs”) ~~was~~that entitle La Jolla to receive up to approximately $3.9 million on the achievement of certain regulatory and sales-based milestones.1 The AcelRx CVRs will be paid in AcelRx common stock or cash at the discretion of AcelRx. La Jolla is also entitled to receive up to approximately 0.2 million shares of AcelRx common stock, if such shares are not used to satisfy certain obligations of Lowell and its security holders made in connection with the acquisition.

16The shares of AcelRx common stock received by La Jolla are considered marketable equity securities, which are measured at fair value on a recurring basis and classified as Level 1 in the ASC Topic 820-10 three-tier fair value hierarchy. Any unrealized gain (loss) is recorded in other income (expense), net. Any potential consideration received in connection with the AcelRx CVRs is contingent upon the achievement of certain regulatory and sales-based milestones. Accordingly, the AcelRx CVRs are deemed a “gain contingency” pursuant to FASB ASC 450, Contingencies, and the Company will record a gain in other income (expense), net upon the achievement of such milestones.

~~The~~In ~~Purchase~~connection ~~Price~~with ~~allocation~~the asclosing of the acquisition, ~~date~~La isJolla ~~presented~~recorded as$0.7 ~~follows~~million of short-term investments and a $0.7 million gain on sale of its non-controlling equity interest in Lowell in other income (expense), net, which is equal to the approximately 1.4 million shares of AcelRx common stock received, multiplied by the closing price of the common stock on the acquisition date. As of March 31, 2022, the fair value of short-term investments was $0.4 million. For the three months ended March 31, 2022, the Company recorded a $0.3 million loss on short-term investments in ~~thousands~~other income (expense):, net.

	July 28,
	2020
Cash	$	42,990
Fair Value of CVRs		2,610
Total Purchase Price	$	45,600
Cash and cash equivalents	$	8,778
Accounts receivable		1,187
Inventory		4,767
Prepaid expenses and other current assets		1,218
Property and equipment		58
Right-of-use lease assets		2,302
Restricted cash		699
Identifiable intangible assets		15,520
Goodwill		20,123
Accounts payable		(1,400	)
Accrued expenses		(2,979	)
Lease liabilities, current portion		(967	)
Lease liabilities, less current portion		(1,420	)
Other noncurrent liabilities		(2,286	)
Total Purchase Price	$	45,600

14. Income Taxes

~~The~~For ~~estimated~~the ~~fair~~three ~~value~~months ended March 31, 2022 and 2021, the Company recorded a provision for income taxes of ~~potential~~$1,000 ~~future~~and ~~cash~~$18,000, ~~payments~~respectively. ~~pursuant~~As toof March ~~the~~31, ~~CVRs~~2022 ~~was~~and ~~based~~December 31, on2021, the Company established a ~~Monte~~full ~~Carlo~~valuation ~~simulation~~allowance against its federal and isstate ~~classified~~deferred astax ~~Level~~assets 3due into the ~~ASC~~uncertainty ~~Topic~~surrounding ~~820-10~~the realization of such assets. There were no unrecognized tax benefits as of March 31, ~~three-tier~~2022 ~~fair~~and ~~value~~December 31, ~~hierarchy~~2021. The Company does not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months.

~~CVRs are measured at fair value on a recurring basis~~15. Subsequent During the three and nine months ended September 30, 2021, the Company recorded losses of $25,000 and $0.4 million, respectively, in other (expense) income in the consolidated statements of operations resulting from the change in fair value of CVRs.Event

~~The~~On ~~Company~~April ~~recorded~~5, a $3.3 million fair value step-up adjustment to Tetraphase’s inventory as of the acquisition date. Raw material components and active pharmaceutical ingredients were recorded based on estimated replacement cost. Finished drug product was valued at estimated selling cost2022, ~~adjusted for costs of selling effort and a reasonable profit allowance for such selling effort from~~ the ~~viewpoint~~Company ofreceived adistributions ~~market participant. This fair value step-up adjustment is recorded as cost~~ of ~~product sales when the inventory is sold to customers, zero and~~ $02.92 million ~~of which was included~~ in ~~cost~~connection ofwith ~~product~~its ~~sales~~non-voting ~~during~~interest ~~the~~in ~~three~~a ~~and~~related ~~nine months ended September 30, 2021, respectively, compared to $1~~party.~~2 million for the three and nine months ended September 30, 2020.~~

Identifiable intangible assets consist of certain technology and trade names acquired from Tetraphase, and include the value of the Harvard, Paratek and Everest Licenses (see Note 10). The acquired intangible assets have definite useful lives and are being amortized on a straight-line basis over an estimated useful life of 10 years.15

Goodwill represents the excess of the Purchase Price over the fair value of the net assets acquired as of the acquisition date. Goodwill represents the value of the stronger platform to increase patient access to the Company’s commercial products and the operational synergies of the combined Company. Goodwill has an indefinite useful life and is not amortized. The goodwill is only deductible for tax purposes if the Company makes a U.S. Internal Revenue Code Section 338 (“Section 338”) election. The Company did not make a Section 338 election.

12. Company-wide Realignments

On May 28, 2020, the Board of Directors of the Company approved a restructuring plan (the “2020 Realignment”) to align its organization with the Company’s sole focus on the commercialization of its products. The 2020 Realignment reduced the Company’s headcount. For the year ended December 31, 2020, total expense was comprised of $4.1 million for one-time termination benefits to the affected employees, including severance and health care benefits, offset by a $0.4 million reversal of non-cash, share-based compensation expense related to forfeited, unvested equity awards. As of September 30, 2021, the Company had made substantially all of the payments related to the 2020 Realignment.

In July 2020, following the acquisition of Tetraphase, the Company incurred one-time charges related to a reduction in the combined Company’s headcount. For the year ended December 31, 2020, total expense was comprised of $3.1 million for one-time termination benefits to the affected employees, including severance and health care benefits. As of September 30, 2021, the Company had made substantially all of the payments related to this reduction in headcount.

13. Income Taxes

For the three and nine months ended September 30, 2021, the Company recorded a provision for income taxes of $31,000 and $49,000, respectively. For the three and nine months ended September 30, 2020, the Company did not record a provision for income taxes. As of September 30, 2021 and December 31, 2020, the Company established a full valuation allowance against its federal and state deferred tax assets due to the uncertainty surrounding the realization of such assets. There were no unrecognized tax benefits as of September 30, 2021 and December 31, 2020. The Company does not anticipate there will be a significant change in unrecognized tax benefits within the next 12 months.

14. Subsequent Event

On November 2, 2021, La Jolla consummated the change of its corporate domicile from California to Delaware, as described in more detail in La Jolla’s Definitive Proxy Statement on Schedule 14A filed with the SEC on June 4, 2021.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and the related notes and other financial information included in our Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 89, ~~2021~~2022 (the “Form 10-K”).

Forward-looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, and such statements may involve substantial risks and uncertainties. All statements, other than statements of historical facts included in this Quarterly Report on Form 10-Q, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, future expenses, financing needs, plans or intentions relating to acquisitions, business trends and other information referred to under this section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “anticipate,” “target,” “forecast” or the negative of these terms and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts and reflect our current views with respect to future events. Forward-looking statements are also based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

There are a number of risks, uncertainties and other important factors that could cause our actual results to differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. Such risks, uncertainties and other factors are described under “Risk Factors” in Item 1A of our Form 10-K. We caution you that these risks, uncertainties and other factors may not contain all of the risks, uncertainties and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will affect us or our business in the way expected. All forward-looking statements in this Quarterly Report on Form 10-Q apply only as of the date made and are expressly qualified in their entirety by the cautionary statements included in this Quarterly Report on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances.

Business Overview

La Jolla Pharmaceutical Company is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™® (angiotensin II) injection is approved by the U.S. Food and Drug Administration (“FDA”) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA™® (eravacycline) for injection is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older.

Product Portfolio

(1) For U.S. and European approval (2) U.S.: GIAPREZA is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock European Union: GIAPREZA is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies (3) U.S.: XERAVA is a tetracycline class antibacterial indicated for the treatment of cIAIs in patients 18 years of age and older European Union: XERAVA is indicated for the treatment of cIAI in adults

~~(2) U.S.:~~ GIAPREZA® is(angiotensin ~~a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock~~II)

~~European~~GIAPREZA® (angiotensin ~~Union:~~II) injection is approved by the FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is ~~indicated~~approved by the European Commission (“EC”) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body’s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system (“RAAS”), which in turn regulates blood pressure. GIAPREZA is marketed in the U.S. by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary, and is marketed in Europe by PAION Deutschland GmbH on behalf of La Jolla Pharma, LLC.

~~(3) U.S.:~~ XERAVA® ~~is a tetracycline class antibacterial indicated for the treatment of cIAIs in patients 18 years of age and older~~(eravacycline)

~~European~~XERAVA® ~~Union:~~(eravacycline) ~~XERAVA~~for injection is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older. XERAVA is approved by the EC for the treatment of cIAI in adults. XERAVA is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla, and is marketed in Europe by PAION Deutschland GmbH on behalf of Tetraphase. Everest, the Company’s licensee for mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines, submitted an NDA in China, which was accepted by the China National Medical Products Administration (“NMPA”) in March 2021. XERAVA was approved in Singapore by the Health Science Authority in April 2020.

GIAPREZA™ (angiotensin II)

GIAPREZA™ (angiotensin II) injection is approved by the FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is approved by the European Commission (“EC”) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body’s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system (“RAAS”), which in turn regulates blood pressure. GIAPREZA is marketed in the U.S. by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary, and is marketed in Europe by PAION Deutschland GmbH on behalf of La Jolla Pharma, LLC.

XERAVA™ (eravacycline)

XERAVA™ (eravacycline) for injection is approved by the FDA as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older. XERAVA is approved by the EC for the treatment of cIAI in adults. XERAVA is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla, and is marketed in Europe by PAION Deutschland GmbH on behalf of Tetraphase. Everest, the Company’s licensee for mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines, recently submitted an NDA in China, which was accepted by the China National Medical Products Administration (“NMPA”) in March 2021.

Product Candidates

In connection with the acquisition of Tetraphase, we acquired the following product candidates that are in early stage clinical or preclinical development: (1i) TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; (2ii) TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and (3) TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. At this time, there are no active studies nor anticipated future studies for any of these product candidates. We intend to seek out-license opportunities for these product candidates; however, at this time, we are unable to predict the likelihood of successfully out-licensing any of these product candidates.

2017

~~Components~~pneumonia; and (iii) TP-2846, an IV formulation of ~~Our~~a ~~Results~~tetracycline for the treatment of ~~Operations~~acute myeloid leukemia. At this time, there are no active studies nor anticipated future studies for any of these product candidates. We intend to seek out-license opportunities for these product candidates; however, at this time, we are unable to predict the likelihood of successfully out-licensing any of these product candidates.

Results of Operations

The following table summarizes our results of operations for each of the periods below (in thousands):

	Three Months Ended									~~Nine Months Ended~~
	September 30,									September 30,
	March 31,
	2021			2020			Change			2021			2020			Change
	2022			2021			Change
Net product sales	$	1110,~~781~~409		$	98,~~072~~637		$	21,~~709~~772		$	~~31,477~~		$	~~22,468~~		$	~~9,009~~
License and other revenue		~~1,533~~16			-25,500			1(25,~~533~~484	)		~~32,033~~			-			~~32,033~~
Cost of product sales		2,~~031~~165			2,~~489~~731			(~~458~~566	)		~~6,918~~			~~4,013~~			~~2,905~~
Cost of license and other revenue		~~841~~5			-3,600			~~841~~(3,595	)		~~4,441~~			-			~~4,441~~
Selling, general and administrative expense		810,~~632~~274			128,~~493~~755			(31,~~861~~519	)		~~26,383~~			~~29,322~~			~~(2,939~~	)
Research and development expense		~~1,285~~27			31,~~617~~558			(21,~~332~~531	)		~~3,957~~			~~21,581~~			~~(17,624~~	)
Other (expense) income, net		(2,754	)		(2,233	)		(521	)		(5,871	)		(3,495	)		(2,376	)
Other income (expense), net		2,049			(3,057	)		5,106
Provision for income taxes		311			-18			31(17	)		49			-			49
Net income (loss)	$	(2,260	)	$	(11,760	)	$	9,500		$	15,891		$	(35,943	)	$	51,834
Net income	$	2		$	14,418		$	(14,416	)

La Jolla acquired Tetraphase, which commercialized XERAVA, on July 28, 2020. La Jolla’s consolidated financial results for the three and nine months ended September 30, 2020 exclude the financial results of Tetraphase prior to July 28, 2020.

Net Product Sales

Net product sales consist of revenue recognized from sales of GIAPREZA and XERAVA to hospitals and other healthcare organizations in the U.S., generally through a network of specialty ~~and wholesale~~ distributors. These specialty ~~and wholesale~~ distributors are considered our customers for accounting purposes.

For the three months ended March 31, 2022, La Jolla’s net product sales were $1110.84 million ~~and~~compared to $318.56 million for the ~~three~~same ~~and~~period ~~nine~~in ~~months~~2021, ~~ended~~an ~~September~~increase ~~30,~~of ~~2021,~~21%. ~~respectively,~~GIAPREZA ~~compared~~U.S. tonet ~~$9.1~~product ~~million~~sales ~~and~~were $227.57 million, ~~respectively,~~ for the ~~same~~three ~~periods~~months inended ~~2020~~March 31, 2022 compared to $6.8 Lamillion ~~Jolla~~for ~~acquired~~the ~~Tetraphase,~~same ~~which~~period ~~commercialized~~in ~~XERAVA~~2021, onan ~~July~~increase ~~28,~~of ~~2020~~13%. ~~Net~~XERAVA U.S. net product sales were $2.7 million for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2020~~2022 ~~excludes~~compared ~~XERAVA~~to $1.8 million for the same period ~~prior~~in 2021, an increase of 50%. The increase in GIAPREZA and XERAVA U.S. net product sales is primarily due to ~~July~~an ~~28,~~increase ~~2020~~in the number of vials sold to our customers.

GIAPREZA U.S. net sales were $8.9 million and $24.3 million for the three and nine months ended September 30, 2021, respectively, compared to $7.2 million and $20.6 million for the same periods in 2020. GIAPREZA U.S. net sales increased during the three and nine months ended September 30, 2021 compared to the same periods in 2020 due to an increase in the number of vials sold to our customers. XERAVA U.S. net sales were $2.9 million and $7.2 million for the three and nine months ended September 30, 2021, compared to $1.9 million for the three and nine months ended September 30, 2020.

License and Other Revenue

License and other revenue consists of revenue from out-license agreements with counterparties to develop and/or commercialize our products in territories outside of the U.S. in exchange for: (i) nonrefundable, upfront license fees; (ii) development, regulatory or commercial milestone payments; and/or (iii) sales-based royalties. License and other revenue also consists of revenue from commercial supply agreements with our out-licensees to supply a minimum quantity of our products in territories outside the U.S. in exchange for: (i) nonrefundable, upfront fees; and/or (ii) the reimbursement of manufacturing costs, plus a margin in certain cases.

LaFor ~~Jolla’s license and other revenue was $1.5 million for~~ the three months ended ~~September~~March 3031, ~~2021~~2022, ~~which consists of the reimbursement of manufacturing costs in connection with commercial supply agreements with our out-licensees.~~ La Jolla’s license and other revenue was $3216,000 compared to $25.05 million for the ~~nine~~same ~~months~~period ~~ended~~in ~~September~~2021. ~~30,~~The 2021, ~~which~~period ~~consists~~included ~~of: (i)~~ a $22.5 million upfront ~~cash~~ payment inand ~~connection with the PAION License; (ii) $5.0 million for the transfer of certain XERAVA-related manufacturing know-how to Everest in connection with the Everest commercial supply agreement; (iii)~~ a $3.0 million ~~regulatory~~ milestone ~~cash~~ payment received in connection with the ~~Everest~~Company’s ~~License;~~agreements ~~and~~with ~~(iv)~~PAION ~~$1.5~~AG ~~million~~and ~~for~~Everest ~~the~~Medicines ~~reimbursement~~Limited ofcovering ~~manufacturing costs in connection with commercial supply agreements with our out~~ex-~~licensees~~U.S. Larights ~~Jolla~~to ~~did~~GIAPREZA ~~not record license~~ and ~~other revenue during the three and nine months ended September 30, 2020~~XERAVA.

Cost of Product Sales

Cost of product sales consists primarily of expense associated with: (i) manufacturing; (ii) royalties payable to George Washington University, Harvard University and Paratek Pharmaceuticals, Inc.; (iii) shipping and distribution; and (iv) the inventory fair value step-up adjustment recorded in connection with the acquisition of Tetraphase~~; and (iv) shipping and distribution~~.

For the three months ended March 31, 2022, La Jolla’s cost of product sales ~~were~~ was $2.02 million ~~and $6.9~~ ~~million for the three and nine months ended September 30, 2021, respectively,~~ compared to $2.57 million ~~and $4.0~~ ~~million, respectively,~~ for the same ~~periods~~period in ~~2020.~~ ~~Cost of product sales for the three and nine months ended September 30, 2020 excludes XERAVA prior to July 28, 2020~~2021. ~~For~~The ~~the three and nine months ended September 30,~~ 2021, ~~cost~~period ofincluded ~~product~~a ~~sales includes zero and~~ $0.9 million, ~~respectively, of the~~ inventory fair value step-up adjustment recorded in connection with the acquisition of Tetraphase,. ~~compared~~No tosuch ~~$1.2~~adjustment ~~million~~was included in costs of product sales for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2020~~2022.

Cost of License and Other Revenue

Cost of license and other revenue consists of amounts due under in-license agreements and commercial supply agreements in connection with license and other revenue from commercially approved product. Cost of license and other revenue recognized in connection with product that is not commercially approved is recorded as research and development expense.

LaFor ~~Jolla’s cost of license and other revenue was $0.8 million for~~ the three months ended ~~September~~March 3031, ~~2021~~2022, ~~which consists of manufacturing costs in connection with commercial supply agreements with our out-licensees.~~ La Jolla’s cost of license and other revenue was $45,000 compared to $3.46 million for the ~~nine~~same ~~months~~period ~~ended~~in ~~September 30,~~ 2021,. ~~which~~This ~~consists~~decrease ~~of:~~is ~~(i)~~due ~~$3.6~~to ~~million~~a ~~for~~decrease in amounts due under the George Washington University and Harvard University license agreements in connection with the upfront cash payment received ~~from~~pursuant to the PAION ~~License;~~AG ~~and (ii) $0.8 million for manufacturing costs in connection with commercial supply agreements with our~~ out-~~licensees. La Jolla did not record cost of~~ license ~~and other revenue during the three and nine months ended September 30, 2020~~agreement.

Selling, General and Administrative Expense

Selling, general and administrative expense consists of non-personnel and personnel expenses. Non-personnel-related expense includes expense related to: (i) sales and marketing costs such as speaker programs, advertising and promotion; (ii) professional fees for legal, patent, consulting, ~~accounting~~surveillance, regulatory filings and ~~audit~~accounting; ~~services~~(iii) amortization of intangible assets; and (~~iii~~iv) facilities and information technology. Personnel-related expense includes expense related to salaries, benefits and share-based compensation for personnel engaged in sales, finance and administrative functions. We ~~do not~~ expect our selling, general and administrative expense to increase ~~significantly~~modestly in ~~the~~2022 ~~near~~to ~~term~~support growing net product sales for both GIAPREZA and XERAVA.

The following table summarizes these expenses for each of the periods below (in thousands):

	Three Months Ended							~~Nine Months Ended~~
	September 30,							September 30,
	March 31,
	2021		2020		Change			2021		2020		Change
	2022		2021		Change
Non-personnel expense:
Sales and marketing	$	1,~~534~~357	$	~~782~~1,195	$	~~752~~162		$	~~4,044~~	$	~~2,593~~	$	~~1,451~~
Professional fees		1,~~113~~585		1,~~946~~528		~~(833~~57	)		~~3,907~~		~~4,173~~		~~(266~~	)
Facility		~~116~~67		~~941~~14		~~(825~~53	)		~~235~~		~~1,988~~		~~(1,753~~	)
Other		~~962~~1,048		~~1,045~~792		~~(83~~256	)		~~2,565~~		~~1,970~~		~~595~~
Total non-personnel expense		34,~~725~~057		43,~~714~~529		~~(989~~528	)		~~10,751~~		~~10,724~~		27
Personnel expense:
Salaries, bonuses and benefits		4,~~013~~972		4,~~558~~386		~~(545~~586	)		~~12,921~~		~~11,880~~		~~1,041~~
One-time charges for reductions in headcount		-		2,524		(2,524	)		-		4,551		(4,551	)
Share-based compensation expense		1,245		840		405
Share-based compensation expense		894		697		197			2,711		2,167		544
Total personnel expense		6,217		5,226		991
Total personnel expense		4,907		7,779		(2,872	)		15,632		18,598		(2,966	)
Total selling, general and administrative expense	$	10,274	$	8,755	$	1,519
Total selling, general and administrative expense	$	8,632	$	12,493	$	(3,861	)	$	26,383	$	29,322	$	(2,939	)

During the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021~~2022, total selling, general and administrative non-personnel expense ~~decreased~~increased compared to the same period in ~~2020~~2021 primarily as a result of: (i) ~~decreases~~an increase in ~~facility-related~~speaker ~~expenses~~programs, asadvertising aand ~~result~~other ofpromotional ~~the~~activities ~~termination~~to ofsupport ~~our~~growing ~~lease~~net product sales for ~~office~~both GIAPREZA and ~~laboratory~~XERAVA; ~~space~~(ii) an increase in ~~San~~non-personnel ~~Diego,~~allocations ~~California~~to general and administrative activities; and (iii) an increase in other administrative expenses.

22During the three months ended March 31, 2022, total selling, general and administrative personnel expense increased compared to the same period in 2021 primarily as a result of: (i) an increase in the average per cost of employee; (ii) an increase in personnel allocations to general and administrative activities; and (iii) an increase in share-based compensation expense resulting from an increase in the volume and grant date fair value of stock options granted to employees in connection with their annual performance.

effective August 31, 2020; and (ii) decreases in professional fee-related expenses; partially offset by increases in expenses resulting from the inclusion of Tetraphase-related costs, which are excluded from La Jolla’s financial results for the three and nine months ended September 30, 2020 prior to July 28, 2020. During the three and nine months ended September 30, 2020, La Jolla incurred acquisition-related expenses of $0.9 million.19

During the three months ended September 30, 2021, total selling, general and administrative personnel expense decreased compared to the same period in 2020 primarily as a result of: (i) one-time charges in 2020 resulting from a reduction of headcount from combining La Jolla and Tetraphase personnel in July 2020; and (ii) reduced headcount. During the nine months ended September 30, 2021, total selling, general and administrative personnel expense decreased compared to the same period in 2020 primarily as a result of one-time charges in 2020 resulting from: (i) a reduction of headcount from a Company-wide realignment in May 2020; and (ii) a reduction of headcount combining La Jolla and Tetraphase personnel in July 2020; partially offset by an increase in the average cost per employee.

Research and Development Expense

Research and development expense consists of non-personnel and personnel expenses. Non-personnel-related expense includes expense related to: (i) manufacturing development; (ii) amounts due under in-license agreements for drug product that is not commercially approved; ~~(iii) facilities~~ and ~~information technology; and~~ (iviii) conducting ~~clinical~~post-marketing pediatric studies. Personnel-related expense includes expense related to salaries, benefits and share-based compensation for personnel engaged in research and development functions. We do not expect our research and development expense to ~~decrease~~be insignificant ~~the~~going ~~near term~~forward.

~~The~~For ~~following~~the ~~table~~three ~~summarizes~~months ~~these~~ended ~~expenses~~March ~~for~~31, ~~each~~2022, oftotal research and development expense was $27,000 compared to $1.6 million for the ~~periods~~same ~~below~~period in 2021. This decrease is primarily due to: (i) a $0.6 million decrease in ~~thousands~~amounts due under in-license agreements for drug product that was not commercially approved; (ii): a $0.4 million decrease in manufacturing development and post-marketing pediatric study expenses; and (iii) a $0.4 million decrease in total research and development personnel expense, including share-based compensation expense, due to a decrease in personnel allocations to research and development activities.

	Three Months Ended							Nine Months Ended
	September 30,							September 30,
	2021		2020		Change			2021		2020		Change
Non-personnel expense:
GIAPREZA	$	265	$	832	$	(567	)	$	744	$	3,675	$	(2,931	)
XERAVA		311		511		(200	)		727		511		216
LJPC-401		-		-		-			102		1,531		(1,429	)
LJPC-0118		-		9		(9	)		16		926		(910	)
Facility		2		312		(310	)		7		2,872		(2,865	)
Other		126		437		(311	)		852		1,111		(259	)
Total non-personnel expense		704		2,101		(1,397	)		2,448		10,626		(8,178	)
Personnel expense:
Salaries, bonuses and benefits		300		643		(343	)		905		5,111		(4,206	)
One-time charges for reductions in headcount		-		182		(182	)		-		2,626		(2,626	)
Share-based compensation expense		281		691		(410	)		604		3,218		(2,614	)
Total personnel expense		581		1,516		(935	)		1,509		10,955		(9,446	)
Total research and development expense	$	1,285	$	3,617	$	(2,332	)	$	3,957	$	21,581	$	(17,624	)

Other Income (Expense), Net

~~During~~Other ~~the~~income ~~three and nine months ended September 30~~(expense), ~~2021,~~net ~~total~~consists ~~research~~primarily ~~and~~of ~~development non-personnel expense decreased compared to~~ the ~~same periods in 2020 primarily as a result of~~following: (i) ~~decreases~~interest inexpense ~~program-related~~accrued ~~expenses~~for ~~as we de-prioritized~~ our ~~product~~deferred ~~candidates~~royalty ~~and~~obligation; ~~focused~~(ii) onincome ~~the~~from ~~commercialization~~distributions ofreceived ~~GIAPREZA~~in ~~and~~connection ~~XERAVA;~~with ~~(ii)~~our ~~decreases~~non-voting interest in ~~manufacturing~~a ~~development-~~related ~~expenses for GIAPREZA~~party; ~~and~~ (iii) ~~decreases~~a ingain ~~facility-related~~on ~~expenses~~the ~~primarily~~forgiveness asof aPaycheck ~~result~~Protection ofProgram ~~the~~loan ~~termination~~(“PPP ofLoan”); ~~our~~and ~~lease~~(iv) ~~for~~gains ~~office~~ and/or ~~laboratory~~losses ~~space~~resulting from changes in ~~San~~the ~~Diego,~~fair ~~California~~value ~~effective~~of ~~August~~contingent ~~31,~~value ~~2020~~rights (“CVRs”).

~~During~~For the three ~~and nine~~ months ended ~~September~~March 3031, ~~2021~~2022, ~~total~~other ~~research~~income ~~and development personnel~~ (expense), ~~including~~net ~~share-based~~was ~~compensation~~$2.0 ~~expense,~~million ~~decreased~~ compared to $(3.1) million for the same ~~periods~~period in ~~2020~~2021. asThis aincrease ~~result~~is ofprimarily due to: (i) ~~reduced~~a ~~headcount;~~$2.3 ~~and~~million increase due to a gain on the forgiveness of the PPP Loan by the U.S. Small Business Administration; (ii) ~~one~~a $1.6 million increase in the receipt of distributions in connection with the Company’s non-~~time~~voting ~~charges~~interest in ~~2020~~a ~~resulting~~related ~~from:~~party; (aiii) a ~~reduction~~$0.7 ofmillion ~~headcount~~gain ~~from~~on athe ~~Company~~sale of our non-~~wide~~controlling ~~realignment~~equity ininterest ~~May~~of ~~2020~~Lowell; and (biv) a ~~reduction~~$0.6 ofmillion ~~headcount~~net ~~combining~~increase Lain ~~Jolla~~the ~~and~~change ~~Tetraphase~~in ~~personnel~~fair invalue ~~July~~of ~~2020~~CVRs.

Research and development expense for the three and nine months ended September 30, 2020 excludes Tetraphase-related costs prior to July 28, 2020.

Other (Expense) Income, Net

Other (expense) income, net consists primarily of the following: (i) interest expense accrued for our deferred royalty obligation; (ii) income from distributions received in connection with our non-voting profits interest in a related party; (iii) gains and losses associated with the disposal of certain property and equipment; (iv) gains and losses from changes in the fair value of contingent value rights (“CVRs”); and (v) interest income generated from cash held in savings accounts.

During the three months ended September 30, 2021, other (expense) income, net was $(2.8) million, compared to $(2.2) million for the same period in 2020. This $0.6 million decrease in other (expense) income, net was primarily due to: (i) a $0.8 million decrease in gain on disposal of certain property and equipment; and (ii) a $0.2 million increase in interest expense for our deferred royalty obligation; partially offset by a $0.5 million decrease in loss on short-term investments.

During the nine months ended September 30, 2021, other (expense) income, net was $(5.9) million, compared to $(3.5) million for the same period in 2020. This $2.4 million decrease in other (expense) income, net was primarily due to: (i) a $1.6 million decrease in the receipt of distributions in connection with the Company’s non-voting profits interest in a related party; (ii) a $0.6 million increase in interest expense for our deferred royalty obligation; and (iii) a $0.2 million decrease in interest income generated from cash held in savings accounts.

Liquidity and Capital Resources

As of ~~September~~March ~~30, 2021 and December~~ 31, ~~2020~~2022, La Jolla had ~~cash~~$44.6 ~~and~~million of cash, cash equivalents ofand short-term investments compared to $46.87 million ~~and~~as ~~$21~~of December 31, 2021. The $2.1 million decrease in cash, ~~respectively~~cash equivalents and short-term investments is primarily due to $2.5 ~~Based~~million onof ~~our~~net ~~current~~cash ~~operating~~provided ~~plans~~by ~~and~~operating ~~projections~~activities, weoffset ~~believe~~by ~~that~~$5.2 ~~our~~million ~~existing~~in ~~cash~~purchases ~~and~~of the Company’s common stock under its stock repurchase plan. For the three months ended March 31, 2022, La Jolla’s net cash ~~equivalents~~provided ~~will~~by beoperating ~~sufficient~~activities was $2.5 million compared to ~~fund~~$17.2 ~~operations~~million for atthe ~~least~~same ~~one~~period ~~year~~in ~~from~~2021. ~~the~~The ~~date~~2021 ~~this~~period ~~Quarterly~~included ~~Report~~a on$16.8 ~~Form~~million ~~10-Q~~net isupfront ~~filed~~payment ~~with~~and ~~the~~a ~~SEC~~$3.0 ~~The~~million ~~Company~~milestone ~~expects~~payment toreceived ~~fund~~in ~~future~~connection ~~operations~~with the Company’s agreements with ~~existing~~PAION ~~cash~~AG orand ~~cash~~Everest ~~generated~~Medicines ~~from~~Limited ~~operations~~covering ex-U.S. rights to GIAPREZA and XERAVA.

LaBased ~~Jolla’s~~on ~~net~~our ~~cash~~current ~~provided by (used for)~~ operating ~~activities~~plans ~~for the three~~ and ~~nine months ended September 30~~projections, ~~2021~~we ~~was~~believe ~~$0.8~~that ~~million~~our ~~and~~existing ~~$25.1 million~~cash, ~~respectively,~~cash ~~compared~~equivalents ~~to $(9.8) million~~ and ~~$(30.4)~~short-term ~~million,~~investments ~~respectively,~~will ~~for~~be ~~the~~sufficient ~~same~~to ~~periods~~fund inoperations ~~2020.~~for Laat ~~Jolla’s~~least ~~net~~one ~~cash~~year ~~provided~~from ~~by (used for) operating activities for~~ the ~~three~~date ~~and~~this ~~nine~~Quarterly ~~months~~Report ~~ended~~on ~~September~~Form ~~30, 2021, excluding upfront net receipts in connection with out~~10-~~license~~Q ~~agreements~~is ~~and~~filed ~~commercial supply agreements, payments related to reductions in headcount, and transaction costs associated~~ with the ~~Tetraphase acquisition, was $1~~SEC.1 ~~million~~The ~~and~~Company ~~$1.5~~expects ~~million, respectively, compared~~ to ~~$(5.6)~~fund ~~million~~future ~~and~~operations ~~$(21.6)~~with ~~million,~~existing ~~respectively,~~cash ~~for~~or ~~the~~cash ~~same~~generated ~~periods~~from ~~in 2020~~operations. ~~The exclusions above are comprised of the following:~~

• Upfront net receipts in connection with out-license agreements were zero and $18.4 million for the three and nine months ended September 30, 2021, respectively, and zero for the same periods in 2020.

• Upfront net receipts in connection with commercial supply agreements were zero and $6.8 million for the three and nine months ended September 30, 2021, and zero for the same periods in 2020.

• Payments related to reductions in headcount were $0.3 million and $1.6 million for the three and nine months ended September 30, 2021, respectively, and $3.3 million and $7.9 million, respectively, for the same periods in 2020.

• Payments related to transaction costs associated with the Tetraphase acquisition were zero for the three and nine months ended September 30, 2021, and $0.9 million for the three and nine months ended September 30, 2020.

The amount and timing of additional future funding needs, if any, will depend on many factors, including the success of our commercialization efforts for GIAPREZA and XERAVA and our ability to control expenses. If necessary, we intend to raise additional capital through equity or debt financings. We can provide no assurance that additional financing will be available to us on favorable terms, or at all.

Contractual Obligations

HealthCare Royalty Partners Royalty Agreement

In May 2018, we closed a $125.0 million royalty financing agreement (the “Royalty Agreement”) with HealthCare Royalty Partners (“HCR”). Under the terms of the Royalty Agreement, we received $125.0 million in exchange for tiered royalty payments on worldwide net sales of GIAPREZA. HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA beginning April 1, 2018. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. Through December 31, 2021, the maximum royalty rate was 10%. Starting January 1, 2022, the maximum royalty rate increased by 4%, and starting January 1, 2024, the maximum royalty rate may increase by an

2420

~~Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. Through December 31, 2021, the royalty rate will be a maximum of~~additional ~~10%. Starting January 1, 2022, the maximum royalty rate may increase by~~ 4% if an agreed-upon, cumulative net product sales threshold has not been met~~, and, starting January 1, 2024, the maximum royalty rate may increase by an additional 4% if a different agreed-upon, cumulative net product sales threshold has not been met~~. The Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million. The Royalty Agreement expires upon the first to occur of January 1, 2031 or when the maximum aggregate royalty payments have been made. The Royalty Agreement was entered into by our wholly owned subsidiary, La Jolla Pharma, LLC, and HCR has no recourse under the Royalty Agreement against La Jolla Pharmaceutical Company or any assets other than GIAPREZA.

In-license Agreements

George Washington University

Harvard University

Paratek Pharmaceuticals, Inc.

Out-license Agreements

PAION AG

OnIn January ~~12,~~ 2021, La Jolla Pharmaceutical Company and certain of its wholly owned subsidiaries, including La Jolla Pharma, LLC, and Tetraphase Pharmaceuticals, Inc., entered into an exclusive license agreement (the “PAION License”) with PAION AG and its wholly owned subsidiary (collectively, “PAION”) ~~(the “PAION License”)~~. Pursuant to the PAION License, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland (collectively, the “PAION Territory”). La Jolla has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax, and is entitled to receive potential commercial milestone payments of up to $109.5 million and double-digit tiered royalty payments. In addition, royalties payable under the PAION License will be subject to reduction on account of generic competition and after patent expiration in a jurisdiction. La Jolla recognized the upfront cash payment of $22.5 million as license and other revenue for the three months ended March 31, 2021, and the 15% refundable withholding tax of $3.4 million was recorded as an other current asset as of March 31, 2022 and December 31, 2021. Pursuant to the PAION

2521

~~of up to $109.5 million and double-digit tiered royalty payments. In addition, royalties payable under the PAION~~ License ~~will be subject to reduction on account of generic competition and after patent expiration in a jurisdiction. Pursuant to the PAION License~~, PAION will be solely responsible for the future development and commercialization of GIAPREZA and XERAVA in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA and XERAVA in the PAION Territory. The Company has not received any payments from PAION related to either royalties or commercial milestones.

Everest Medicines Limited

In February 2018, the Company entered into a license agreement with Everest, which was subsequently amended and restated (the “Everest License”). Pursuant to the Everest License, the Company granted Everest an exclusive license to develop and commercialize XERAVA for the treatment of cIAI and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the “Everest Territory”). The Company is eligible to receive an additional $8.0 million regulatory milestone payment and up to an aggregate of $20.0 million in sales milestone payments. The Company is also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (1i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (2ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (3iii) 10 years after the first commercial sale of a product in such jurisdiction in the Everest Territory. In March 2021, the Company received a $3.0 million milestone payment associated with the submission of an NDA with the China NMPA for XERAVA for the treatment of cIAI in patients in China. XERAVA was approved in Singapore by the Health Science Authority in April 2020.

In May 2021, the Company entered into a commercial supply agreement with Everest whereby the Company will supply Everest a minimum quantity of XERAVA through December 31, 2023 and will transfer to Everest certain XERAVA-related manufacturing know-how. Pursuant to the supply agreement: (i) the Company has received $6.8 million of upfront payments comprised of: (1) a $4.0 million upfront technology transfer payment; and (2) a $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022; (ii) the Company ~~will~~has ~~receive~~received an additional $1.0 million technology transfer payment byin January 30, 2022; and (iii) the Company will be reimbursed for direct and certain indirect manufacturing costs at 110% of costs through December 31, 2023. The Company recognized the $5.0 million of technology transfer-related payments as license and other revenue during the ~~nine~~year ~~months~~ ended ~~September~~December 3031, 2021 as Everest obtained control of the XERAVA-related manufacturing know-how prior to ~~September~~December 3031, 2021. The Company recognized the $2.8 million partial prepayment for XERAVA that is expected to be delivered to Everest during 2022 as deferred revenue as of ~~September~~March 3031, 2022 and December 31, 2021 as the performance obligation to deliver XERAVA ~~has~~had not yet been satisfied.

Off−Balance Sheet Arrangements

We have no off−balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in our financial condition, expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Estimates

We believe the estimates, assumptions and judgments involved in the accounting policies described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Item 7 of our Form 10-K for the year ended December 31, ~~2020~~2021 are most critical to understanding and evaluating our reported financial results. During the ~~nine~~three months ended ~~September 30~~March 31, ~~2021~~2022, there have been no material changes to the critical accounting policies and estimates as described in Item 7 of our Form 10-K for the year ended December 31, ~~2020~~2021.

Recent Accounting Pronouncements

See Note 2 to our condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q.

2622

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company, as defined by Rule 12b-2 under the Securities and Exchange Act of 1934 and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.

Item 4. Controls and Procedures

Management’s Evaluation of our Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and our principal financial and accounting officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures as of ~~September 30~~March 31, ~~2021~~2022, our principal executive officer and principal financial and accounting officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during our most recent quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

2723

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

~~From~~The ~~time~~Company ~~to time, we~~ may periodically become subject to ~~claims~~legal proceedings and ~~litigation~~claims arising in ~~the~~connection ~~ordinary~~with ~~course~~its of business. As Weof ~~are~~March ~~not~~31, a2022, ~~party~~no toclaims ~~any~~or ~~material~~actions ~~legal~~are ~~proceedings~~pending against the Company that, ~~nor~~in the opinion of management, are welikely ~~aware~~to ofhave ~~any~~a material ~~pending~~adverse oreffect ~~threatened~~on ~~litigation~~the Company.

On February 15, 2022, the Company received a paragraph IV notice of certification (the “Notice Letter”) from Gland Pharma Limited (“Gland”) advising that Gland had submitted an Abbreviated New Drug Application (“ANDA”) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA^® in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the “GIAPREZA Patents”), which are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). The Notice Letter alleges that the GIAPREZA Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland’s ANDA.

On March 29, 2022, the Company filed a complaint for patent infringement of the GIAPREZA Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland’s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA is a new chemical entity and the Company filed a complaint for patent infringement within 45 days of receipt of the Notice Letter, the FDA cannot approve Gland’s ANDA any earlier than 7.5 years from the approval of the GIAPREZA NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed. The Company intends to vigorously enforce its intellectual property rights relating to GIAPREZA.

Item 1A. Risk Factors

Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, ~~2020~~2021. There have been no material changes from the risk factors disclosed in Item 1A of our Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

~~None~~On November 17, 2021, La Jolla announced that it would commence a stock repurchase plan for up to $10 million of the Company’s common stock. On March 7, 2022, the Board approved a $5 million increase to the stock repurchase plan from up to $10 million to up to $15 million of the Company’s common stock. The plan has no time limit and can be discontinued at any time. The following table contains information with respect to repurchases made by the Company during the three months ended March 31, 2022:

Period	(a) Total number of shares purchased		(b) Average price paid per share⁽¹⁾		(c) Total number of shares purchased as part of publicly announced plans or programs		(d) Maximum approximate dollar value of shares that may yet be purchased under the plans or programs (in thousands)
January 1, 2022 – January 31, 2022		461,101	$	4.64		461,101	$	9,480
February 1, 2022 – February 28, 2022		405,139	$	4.40		405,139	$	7,699
March 1, 2022 – March 31, 2022		295,698	$	4.25		295,698	$	6,441
Total		1,161,938				1,161,938

⁽¹⁾	Includes commissions

The Company has entered into a Rule 10b5-1 stock repurchase plan for the purpose of establishing a trading plan to purchase the Company’s common stock in a manner that complies with the requirements of Rule 10b5-1(c)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit No.		Exhibit Description
10.1+		Amended Employment Offer Letter by and between La Jolla Pharmaceutical Company and Larry Edwards
3.1		Amended and Restated Certificate of Incorporation of La Jolla Pharmaceutical Company, a Delaware Corporation (incorporated by reference to Exhibit 3.1 to the registrant’s Report on Form 8-K12B filed with the SEC on November 2, 2021)
31.1		Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
3.2		Bylaws of La Jolla Pharmaceutical Company, a Delaware Corporation (incorporated by reference to Exhibit 3.2 to the registrant’s Report on Form 8-K12B filed with the SEC on November 2, 2021)
31.2		Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.1*		Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
31.2*		Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document
32.1**		Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.INS*		Inline XBRL Instance Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
+		Indicates a management contract or compensatory plan or arrangement
104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
		*Filed herewith
		**Furnished herewith

2826

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			La Jolla Pharmaceutical Company
Date:	~~November~~May 416, ~~2021~~2022	By:	/s/ Larry Edwards
			Larry Edwards
			Director, President and Chief Executive Officer
			(principal executive officer)
			/s/ Michael Hearne
			Michael Hearne
			Chief Financial Officer
			(principal financial and accounting officer)

2927

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

Filing Compare · LA JOLLA PHARMACEUTICAL CO